[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 33124
1. Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, Unger JM, Brooks TA, Persky DO, Wilkinson ST, Grogan TM, Rimsza LM: Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica; 2010 Apr;95(4):597-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.
  • BACKGROUND: Translocations involving the MYC gene and increased MYC mRNA levels are associated with poor outcome in diffuse large B-cell lymphoma.
  • DESIGN AND METHODS: Utilizing dual color chromogenic in situ hybridization, we investigated MYC gene copy and chromosome 8 centromere numbers in 52 cases of diffuse large B-cell lymphoma.
  • CONCLUSIONS: This is the first report that low level copy number increases are common in diffuse large B-cell lymphoma and that these changes correlate with MYC mRNA in a statistically significant manner.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):510-18 [10653866.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3594-601 [16081686.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3414-21 [12032779.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1115-29 [12695333.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):519-28 [15160914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] J Biol Chem. 1990 Oct 25;265(30):18538-45 [2211718.001]
  • [Cites] Adv Cancer Res. 1991;56:1-48 [2028839.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Genes Dev. 1994 Feb 15;8(4):465-80 [8125259.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2343-7 [7784082.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):2656-69 [8649373.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31452-7 [8940157.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;224:47-56 [9308227.001]
  • [Cites] J Cutan Pathol. 2006 Apr;33(4):286-92 [16630178.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):498-512 [16890804.001]
  • [Cites] Front Biosci. 2007;12:4409-23 [17485385.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):979-97 [17700562.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] EMBO J. 2008 Jan 9;27(1):277-89 [18059478.001]
  • [Cites] Nat Struct Mol Biol. 2008 Feb;15(2):146-54 [18193062.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5509-14 [18445689.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3425-33 [18544678.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):158-66 [11071868.001]
  • [Cites] Nucleic Acids Res. 1998 Mar 1;26(5):1167-72 [9469822.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Feb 4;327(1):49-56 [15629428.001]
  • [Cites] Arch Pathol Lab Med. 2007;131(1):18-43 [19548375.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6681-90 [19278952.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):994-1004 [2189958.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):114-21 [15642390.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • (PMID = 20378577.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / T32 CA009213; United States / NCI NIH HHS / CA / CA09213
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2857189
  •  go-up   go-down


2. Nixon BK, Kussick SJ, Carlon MJ, Rubin BP: Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm. Mod Pathol; 2005 Aug;18(8):1121-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm.
  • We report the clinicopathological features of two cases of intravascular large B-cell lymphoma involving cutaneous hemangiomas.
  • Biopsies and immunohistochemical evaluation of the hemangiomas revealed extensive involvement by intravascular large B-cell lymphoma.
  • The neoplastic cells were diffusely positive for CD20 in both cases and negative for CD3, pan-cytokeratin (AE1/AE3), epithelial membrane antigen, S-100, Factor VIII-related antigen, CD34 and CD31.
  • Disease was limited to the hemangiomas in both patients.
  • One patient had a recurrence of disease 33 months after initial diagnosis, leading to an autologous stem cell transplant.
  • The other patient is without evidence of disease 27 months after initial diagnosis.
  • Although this is a rare neoplasm, it is important to consider intravascular large B-cell lymphoma in the differential diagnosis of vascular lesions containing intravascular neoplastic cells.
  • [MeSH-major] Hemangioma / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Antigens, CD19 / analysis. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Antigens, CD5 / analysis. DNA-Binding Proteins / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors. Middle Aged. Neoplasm Recurrence, Local. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803190.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / interferon regulatory factor-4; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


3. Yin HF, Li T: [Helicobacter pylori genotypes of gastrointestinal B cell lymphoma]. Beijing Da Xue Xue Bao; 2006 Apr 18;38(2):189-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori genotypes of gastrointestinal B cell lymphoma].
  • OBJECTIVE: To assess the expression of specific virulence-associated Helicobacter pylori (Hp) genotypes. (cag A, vac A, and ice A status) in primary gastrointestinal B cell lymphoma.
  • RESULTS: There were 14 cases of mucosa associated lymphoid tissue lymphoma (MALT-L) (8 in stomach, and 6 in intestine) and 35 cases of diffuse large B cell lymphoma (DLBCL) (21 in stomach, and 14 in intestine) in all.
  • CONCLUSION: High toxicity cag A+Hp strains seem to play a role in the pathogenesis of gastrointestinal B cell lymphoma, whereas vac A m2 may be more associated with MALT-L.
  • Clinical stage was not associated with virulence-associated Hp genotypes.
  • [MeSH-major] Helicobacter pylori / genetics. Lymphoma, B-Cell / microbiology. Stomach Neoplasms / microbiology
  • [MeSH-minor] Genotype. Humans. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / microbiology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617364.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K: Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop; 2009 May;49(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP.
  • To assess the humoral response to the influenza vaccine in patients undergoing R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone) for non-Hodgkin lymphoma (NHL), the anti-hemagglutinin (HA) titer in 7 NHL patients undergoing therapy was compared with those in 10 control group subjects in the 2005/2006 season.
  • Four weeks after vaccination, the HA titers against the influenza type A H1N1 and type B antigens, the same antigens that had been used in the previous seasons, were elevated in all patients treated with R-CHOP.
  • In contrast, there was no increase in the geometric mean titer for type A H3N2 antigen, which was newly included in 2005/2006 season, in the patients treated with R-CHOP, while there was a significant increase in the 10 control subjects (p = 0.014).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Influenza Vaccines / immunology. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies / blood. Antibodies, Monoclonal, Murine-Derived. Antibody Formation. Antigens, Viral / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Hemagglutinins / immunology. Humans. Immunologic Memory. Influenza A Virus, H1N1 Subtype / immunology. Influenza A Virus, H3N2 Subtype / immunology. Male. Middle Aged. Pilot Projects. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474512.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Viral; 0 / Hemagglutinins; 0 / Influenza Vaccines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Morales-Polanco MR, Drijansky-Morgenstern R, Murillo-Meza E, Gómez-Morales E: Primary hepatosplenic large B-cell lymphoma: a rare aggressive tumor. Case Rep Gastroenterol; 2008;2(1):109-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatosplenic large B-cell lymphoma: a rare aggressive tumor.
  • Diffuse large B-cell lymphoma is the most common form of lymphoma.
  • According to a definition of primary extranodal lymphoma with presentation only in extranodal sites, there are reports of large B-cell lymphomas limited to liver or spleen as separate entities, and to date there have been only three documented cases of primary hepatosplenic presentation.
  • Due to a review of the literature and the clinical course of the case reported, we conclude that primary hepatosplenic large B-cell lymphoma has been found predominantly in females older than 60 years.
  • The patients reported had <2 months of evolution prior to diagnosis, prominent B symptoms, splenomegaly in three and hepatomegaly in two, none with lymph node involvement.
  • Because of the previously mentioned data, it can be stated that primary hepatosplenic lymphoma is an uncommon and aggressive form of disease that requires immediate recognition and treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Sep;10(9):1023-33 [10572599.001]
  • [Cites] J Korean Med Sci. 1999 Dec;14(6):671-4 [10642947.001]
  • [Cites] Cancer Invest. 2002;20(5-6):749-53 [12197231.001]
  • [Cites] Age Ageing. 2004 Nov;33(6):637-40 [15381504.001]
  • [Cites] Leukemia. 1998 Jun;12(6):1005-6 [9639437.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Verh Dtsch Ges Pathol. 1992;76:122-5 [1283241.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):869-80 [17509984.001]
  • [Cites] Blood. 1985 Jun;65(6):1469-76 [3873265.001]
  • [Cites] Am J Gastroenterol. 1994 Oct;89(10):1915-6 [7942705.001]
  • [Cites] Ann Clin Lab Sci. 1996 Sep-Oct;26(5):433-6 [8879361.001]
  • [Cites] J Gastroenterol. 1998 Dec;33(6):880-5 [9853565.001]
  • (PMID = 21490848.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3075176
  • [Keywords] NOTNLM ; Hepatosplenic / Large B-cell lymphoma / Primary extranodal lymphoma
  •  go-up   go-down


6. Fujiwara T, Ishizawa K, Kohata K, Yamamoto J, Yamada MF, Kameoka J, Ichinohasama R, Harigae H: Aggressive B-cell lymphoma with dual surface immunoglobulin light-chain expression. Intern Med; 2007;46(17):1458-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive B-cell lymphoma with dual surface immunoglobulin light-chain expression.
  • Dual surface immunoglobulin light-chain expression in B-cell malignant neoplasm is a rare event, and has been predominantly reported in chronic lymphocytic leukemia.
  • Herein, we report a case of aggressive B-cell lymphoma with kappa/lambda-dual surface immunoglobulin light-chain expression of a 69-year-old woman.
  • The lymphoma cells were positive for CD5, CD19, CD20, HLA-DR, Ig kappa and Ig lambda.
  • She was treated with a combination of rituximab and CHOP regimen, but died of the progressive disease.
  • To our knowledge, this is the first case of aggressive B-cell lymphoma showing dual kappa/lambda expression; the possible mechanisms of abnormal light chain expression are discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Immunoglobulin Light Chains / biosynthesis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827849.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin Light Chains; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


7. Li S: Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol; 2009;2(6):508-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.
  • Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK(+) LBCL) represents a distinct subtype of mature B-cell neoplasms in the most recent WHO classification of hematolymphoid neoplasms.
  • With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Feb;174(2):361-70 [19131589.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):770-8 [17439836.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Histopathology. 2007 Jan;50(2):278-82 [17222259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Tumori. 2006 Sep-Oct;92(5):449-51 [17168442.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3275-9 [17094440.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6209-22 [16880530.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3191-6 [16101126.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1128-34 [15902287.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1609-14 [15577680.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9526-31 [11121404.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7 [19088198.001]
  • (PMID = 19636398.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713458
  • [Keywords] NOTNLM ; ALK / Anaplastic lymphoma kinase / CLTC/ALK / diffuse large B-cell lymphoma / t(2;17)
  •  go-up   go-down


8. Gardini A, Saragoni L, La Barba G, Garcea D: Simultaneous occurrence of primary diffuse large B-cell lymphoma and extranodal marginal zone (MALT) B-cell lymphoma in the gallbladder: a case report. Pathologica; 2009 Dec;101(6):230-4
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of primary diffuse large B-cell lymphoma and extranodal marginal zone (MALT) B-cell lymphoma in the gallbladder: a case report.
  • Primary lymphoma of the gallbladder is extremely rare.
  • We present an asymptomatic case of primary combined DLBCL--MALT lymphoma of the gallbladder in a 78-year-old man in whom definitive diagnosis was made with laparotomic cholecystectomy.
  • Preoperative diagnosis was supported by NMR, CT and PET scans.
  • A non-Hodgkin lymphoma with two different coexisting patterns was identified histologically: large diffuse B-cell lymphoma (DLBCL) associated with focal areas of extranodal marginal zone B-cell lymphoma (MALT-type) of the gallbladder.
  • The postoperative course was uneventful and the patient is currently without clinical or radiological signs of disease.
  • In conclusion, a primary gallbladder lymphoma is a rare entity.
  • Radiological findings may be helpful, but cholecistectomy may be necessary for definitive diagnosis.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387709.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F, Haioun C: Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol; 2007 Aug;18(8):1363-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
  • BACKGROUND: High-dose therapy (HDT) with stem-cell support is the reference treatment for relapsed lymphoma, but is not appropriate for all patients.
  • Rituximab, gemcitabine and oxaliplatin are active as single agents in relapsed or refractory lymphoma, and have demonstrated synergistic effects in vitro and in vivo.
  • PATIENTS AND METHODS: Forty-six patients with relapsed or refractory B-cell lymphoma received up to eight cycles of R-GemOx (rituximab 375 mg/m(2) on day 1, gemcitabine 1000 mg/m(2) and oxaliplatin 100 mg/m(2) on day 2).
  • The majority (72%) had diffuse large B-cell lymphoma.
  • Among responders, the probability of being disease free for 2 years was 62%.
  • CONCLUSION: R-GemOx shows promising activity with acceptable toxicity in patients with relapsed/refractory B-cell lymphoma who are not eligible for HDT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496309.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Horváth B, Demeter J, Eros N, Hársing J, Csomor J, Matolcsy A, Bottlik G, Gyori G, Marschalkó M, Kárpáti S: Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. J Am Acad Dermatol; 2009 Nov;61(5):885-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
  • Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system.
  • Most cases are of B-cell origin; T-cell phenotype is extremely rare.
  • Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms.
  • The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab.
  • We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin / blood supply. Vascular Neoplasms / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632742.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


11. Bödör C, Bognár A, Reiniger L, Szepesi A, Tóth E, Kopper L, Matolcsy A: Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol; 2005 May;129(3):373-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma.
  • To determine the possible role of aberrant somatic hypermutation (ASHM) and activation-induced cytidine deaminase (AID) expression in the pathogenesis of mediastinal large B-cell lymphoma (MBL), the mutational status of genes affected by ASHM, including c-MYC, PAX-5 and RhoH, was analysed, and the expression level of AID mRNA in tumour specimens from six patients with MBL was determined.
  • [MeSH-major] Cytidine Deaminase / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics. Somatic Hypermutation, Immunoglobulin
  • [MeSH-minor] B-Cell-Specific Activator Protein. DNA Mutational Analysis. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Gene Expression. Genes, myc / genetics. Humans. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Transcription Factors / genetics. rho GTP-Binding Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842661.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / PAX5 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RhoH protein, human; 0 / Transcription Factors; EC 3.5.4.5 / Cytidine Deaminase; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


12. Lones MA, Raphael M, Perkins SL, Wotherspoon A, Auperin A, Terrier-Lacombe MJ, Sposto R, Weston C, Gerrard M, Patte C, Cairo MS, McCarthy K: Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical quality. J Pediatr Hematol Oncol; 2006 Sep;28(9):568-74
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical quality.
  • In pediatric mature B-cell non-Hodgkin lymphoma, international pathologist diagnostic agreement was previously evaluated using the Revised European-American Lymphoma Classification.
  • Surgical biopsies obtained from international protocol FAB LMB96 Treatment of Mature B-Cell Lymphoma/Leukemia for Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and high-grade B-cell lymphoma Burkitt-like (BLL), were independently reviewed by hematopathologists from 3 national groups (Children's Cancer Group, Société Française d'Oncologie Pédiatrique, and United Kingdom Children's Cancer Study Group) to determine each national diagnosis and a final diagnosis.
  • In conclusion, in pediatric mature B-cell non-Hodgkin lymphoma, international pathologist diagnostic agreement is significantly higher in surgical biopsies with better HTQ.
  • [MeSH-major] Histological Techniques / standards. Lymphoma, B-Cell / diagnosis. Pathology, Surgical / standards. Quality Assurance, Health Care

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006262.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


13. Li T, Medeiros LJ, Lin P, Yin H, Littlejohn M, Im W, Lennon PA, Hu P, Jorgensen JL, Liang M, Guo H, Yin CC: Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. Arch Pathol Lab Med; 2010 May;134(5):759-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China.
  • CONTEXT: Gene expression profiling of diffuse large B-cell lymphoma using complementary DNA microarrays has revealed 2 major prognostic groups in Western countries: germinal center B-cell-like and nongerminal center B-cell-like lymphomas.
  • OBJECTIVE: To study the immunohistochemical features of diffuse large B-cell lymphoma cases from northern China because geographic differences for this disease are known to exist.
  • DESIGN: Morphologic, immunohistochemical, and fluorescence in situ hybridization analyses of 63 cases of diffuse large B-cell lymphoma from northern China.
  • Twenty-one (33%) cases were germinal center B-cell-like lymphoma, and 42 (67%) were nongerminal center B-cell-like lymphoma.
  • BCL2 was expressed more often in nongerminal center B-cell-like disease versus germinal center B-cell-like disease (60% versus 24%, P = .01) and in nodal versus extranodal (64% versus 30%, P = .01) cases.
  • CONCLUSIONS: These results add to what is known about the geographic variation of diffuse large B-cell lymphomas.
  • In northern China, the frequency of the germinal center B-cell-like type and BCL6 expression and/or BCL6 rearrangement is less and the frequency of MYC rearrangement is greater than have been reported in Western countries.
  • [MeSH-major] B-Lymphocytes / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441508.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / RNA, Messenger; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


14. Fujimoto M, Haga H, Okamoto M, Obara E, Ishihara M, Mizuta N, Nishimura K, Manabe T: EBV-associated diffuse large B-cell lymphoma arising in the chest wall with surgical mesh implant. Pathol Int; 2008 Oct;58(10):668-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated diffuse large B-cell lymphoma arising in the chest wall with surgical mesh implant.
  • In Japan, most cases of malignant lymphoma arising in the thorax are pyothorax-associated lymphoma, which develops in patients who have undergone artificial pneumothorax, used in the past as surgical therapy for pulmonary tuberculosis.
  • Pyothorax-associated lymphoma consist mostly of diffuse large B-cell lymphoma and have a strong association with EBV.
  • Herein is reported the case of a diffuse large B-cell lymphoma arising in the left thoracic wall after left lung resection for squamous cell carcinoma and chest wall reconstruction with polyethylene terephthalate (PET) surgical mesh.
  • The patient did not have a clinical history of pyothorax after surgery.
  • The lymphoma cells were of the large cell type and were positive for CD20, EBV-encoded small RNA--in situ hybridization, LMP-1 and EBNA-2.
  • The present case demonstrates that EBV-related B-cell lymphoma can occur after surgery other than artificial pneumothorax.
  • In the present case, long-standing chronic inflammation induced by PET mesh may have been associated with the development of lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / etiology. Polyethylene Terephthalates / adverse effects. Surgical Mesh / adverse effects. Thoracic Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Epstein-Barr Virus Nuclear Antigens / analysis. Fatal Outcome. Humans. In Situ Hybridization. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Male. Neoplasms, Second Primary. RNA, Viral / analysis. Thoracic Wall / pathology. Viral Matrix Proteins / analysis. Viral Proteins / analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801089.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus encoded RNA 1; 0 / Polyethylene Terephthalates; 0 / RNA, Viral; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  •  go-up   go-down


15. Castillo J, Milani C, Pantanowitz L: HIV-associated anaplastic large cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anaplastic large cell lymphoma.
  • : e19563 Background: Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell lymphoma that is generally unrelated to EBV in the non-HIV setting.
  • Based upon anaplastic lymphoma kinase (ALK) expression, the new WHO classification provisionally distinguishes between ALK+ (favorable) and ALK- (unfavorable) ALCL.
  • METHODS: A MEDLINE search for all cases of HIV-associated non-cutaneous ALCL was undertaken.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, ALK expression, molecular studies), EBV coinfection, therapy and outcome (survival, cause of death) were extracted and analyzed.
  • Median CD4+ count was 76 cells/mm3 and HIV viral load 416,500 copies/ml.
  • Many (78%) patients had stage IV disease and B symptoms were reported in 9 cases (50%).
  • T-cell receptor gene rearrangement was present in all cases, CD30 was positive in 22 (96%), and the vast majority (90%) were ALK-negative.
  • Death was caused by either lymphoma progression (42%) or infection (58%).
  • CONCLUSIONS: HIV-associated non-cutaneous ALCL appears to affect younger individuals and is associated with EBV infection in a subset of cases.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated ALCL appears to be related to the absence of ALK expression, advanced stage at presentation with prominent extranodal disease, inadequate therapy including HAART, and poor response to CHOP.
  • Further research is needed to better understand and treat this unique HIV-associated lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961064.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gribbin TE, Senzer N, Raizer JJ, Shen S, Nabors LB, Wiranowska M, Fiveash JB: A phase I evaluation of intravenous (IV) &lt;sup&gt;131&lt;/sup&gt;I-chlorotoxin delivery to solid peripheral and intracranial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14507 Background: Pre-clinical studies demonstrate TM601 binding to glioblastoma, melanoma, and other tumor types in vitro and in vivo (human xenograft tumors in mice).
  • Here we report imaging and safety data from a Phase I clinical trial in patients with recurrent metastatic somatic and/or cerebral solid tumors that received IV <sup>131</sup>I-TM601.
  • Tumor-specific uptake was observed in patients with malignant glioma (7/8), metastatic melanoma (7/7), non-small cell lung cancer (3/4), colon cancer (6/7), pancreatic cancer (2/3), prostate cancer (2/2), breast cancer (1/4) and in one evaluable patient each with transitional cell carcinoma, pleomorphic xanthoastrocytoma and metastatic paraganglioma.
  • Notably, all patients with metastatic cerebral disease showed tumor-specific uptake of systemically injected <sup>131</sup>I-TM601.
  • No uptake was seen in CNS lymphoma (n=1), ovarian (n=2), small cell lung (n=2), or medulllary thyroid cancers (n=1).
  • Based on normal tissue dosimetry from this study, future clinical trials will evaluate safety and therapeutic efficacy in patients with recurrent glioma and metastatic melanoma at doses up to 100 mCi <sup>131</sup>I-TM601 (maximum single dose).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963538.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kim Y, Beynon J: Effect of dosing cycles on safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of dosing cycles on safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three phase III studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961073.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Schmitz N, Ziepert M, Nickelsen M, Wolf SP, Truemper L, Loeffler M, Ho A, Metzner B, Rosenwald A, Pfreundschuh M: Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL). J Clin Oncol; 2009 May 20;27(15_suppl):8564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL).
  • : 8564 Background: T-cell lymphomas represent a heterogeneous group of malignancies difficult to diagnose and to treat.
  • METHODS: Between 1993 and 2006 we treated 329 pts with ALK-positive ALCL (73 pts), ALK-negative ALCL (108 pts), PTCL, NOS (68 pts), AITL (28 pts), NK-/T-cell lymphoma (18 pts), and rare T-cell lymphomas on prospective studies.
  • In younger pts (ALK-positive ALCL were excluded) and good-risk disease (LDH <= N) there was a trend for better EFS after the addition of E to CHOP (EFS 63% vs. 48%, p = 0.065).
  • The MegaCHOEP protocol (Schmitz et al., CANCER 2006) failed to improve treatment results for younger pts with poor-risk disease (EFS at 3 yrs: 25.9%, 95% CI: 10.4-41.4); the prospective study comparing MegaCHOEP with CHOEP-14 was stopped for pts with T-cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Moskowitz CH, Zelenetz A, Schoder H: An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw; 2010 Mar;8(3):347-52
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
  • A significant amount of literature is available on treatment monitoring and response assessment in lymphoma using FDG-PET, yet confusion exists concerning the potential and limitations of FDG-PET for determining the presence of residual disease during chemotherapy (interim FDG-PET).
  • This article reviews the role of interim FDG-PET in 3 important scenarios: untreated diffuse large B-cell lymphoma, untreated Hodgkin lymphoma, and relapsed or refractory aggressive lymphoma in transplant-eligible patients, and provides recommendations on the use of this imaging modality in these settings.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202464.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 34
  •  go-up   go-down


20. Bower M, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Hatzimichael E, Powles S, Crook T: Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts. J Clin Oncol; 2009 May 20;27(15_suppl):8585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts.
  • : 8585 Background: Methylation-dependent transcriptional silencing is an important mechanism of tumour suppressor gene inactivation in neoplasia, including lymphoma.
  • METHODS: Pharmacological "unmasking" of transcriptionally silenced genes in B lymphoma cell lines was achieved using 5' deazacytidine ± Trichostatin A and subsequent analysis of mRNA levels on micro-array.
  • Candidate genes thus identified, were further analysed by qPCR, methylation-specific PCR (MSP) and bisulphite sequencing in B lymphoma cell lines and by MSP in clinical samples from sporadic (immunocompetent) (18 cases) and HIV-infected patients (14 cases).
  • Samples in both patient groups were diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma (BL).
  • Additionally, we analysed 8 cases of marginal zone lymphoma (MZL) from the immunocompetent group.
  • RESULTS: We report the identification of 13 novel genes, not previously described in the literature, which are subject to methylation-dependent transcriptional silencing in high-grade lymphoma and whose expression can be reactivated by demethylating agents.
  • The frequency of methylation in individual genes varied from approximately 10% to 75% in specific lymphoma subtypes, but was in general similar in high grade lymphomas in immunocompetent and HIV-infected hosts.
  • CONCLUSIONS: Using pharmacological reversal of methylation, we have identified a number of genes, not previously implicated in human neoplasia, which are subject to transcriptional silencing in high-grade B lymphomas.
  • Detection of methylated DNA of one or more of these genes may have utility as biomarkers of clinical outcome in each patient group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Al Hawashim N, Al Akwaa A: Coexistence of malakoplakia and multifocal diffuse large B cell lymphoma of colorectum. Colorectal Dis; 2009 Jan;11(1):99-100
Genetic Alliance. consumer health - Malakoplakia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of malakoplakia and multifocal diffuse large B cell lymphoma of colorectum.
  • We report a case of concurrent multifocal diffuse large B cell lymphoma and malakoplakia of colorectum in a 36-year-old man presenting with recurrent bloody diarrhoea.
  • Malakoplakia has been described in association with a variety of malignant and nonmalignant conditions.
  • To the best of our knowledge, this is the third report of coexistence or association of malignant non-Hodgkin lymphoma and malakoplakia in the literature, and the first report ever in the colorectum.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Malacoplakia / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462225.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Xia CQ, Qi M, Xu XF, Li LH, Zhao HY: [Application of flow cytometry in diagnosis of T-cell rich diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Jan;36(1):29-32
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of flow cytometry in diagnosis of T-cell rich diffuse large B-cell lymphoma].
  • OBJECTIVE: To investigate the application of flow cytometry in diagnosis of T-cell rich diffuse large B-cell lymphoma.
  • METHODS: Histopathologic features, immunohistochemical findings and flow cytometry results of three cases of T-cell rich diffuse large B-cell lymphoma were reviewed retrospectively.
  • RESULTS: In CD45-side scatter (SSC) dot plot of the first patient, two different CD45-positive lymphoid cell populations were identified.
  • The bright population consisted of both T and B cells, with a T-cell predominance.
  • The dim population consisted mainly of B cells which showed lambda light chain restriction.
  • In the second patient, CD45-positive cells were subdivided into two groups according to CD45-SSC dot plot.
  • The small population consisted of both T and B cells, with a T-cell predominance.
  • The large population consisted mainly of B cells which showed kappa light chain restriction.
  • In the third patient, CD19-positive cells were subdivided into two groups according to the expression of CD20 in CD19-CD20 dot plot.
  • CONCLUSIONS: Neoplastic B cells can be distinguished from reactive lymphoid cells in T-cell rich diffuse large B-cell lymphoma by flow cytometry, according to a number of parameters which include intensity of antigen expression, loss of antigens, expression of non-B-cell lineage antigens, patterns of forward scatter (FSC) and/or SSC, and expression of immature B-cell antigens.
  • [MeSH-major] Antigens, CD45 / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. T-Lymphocytes / pathology
  • [MeSH-minor] Aged. Antigens, CD19 / metabolism. Antigens, CD20 / metabolism. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunoglobulin lambda-Chains / metabolism. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374235.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Immunoglobulin lambda-Chains; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


23. Perez M, Pacchiarotti A, Frontani M, Pescarmona E, Caprini E, Lombardo GA, Russo G, Faraggiana T: Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. Br J Dermatol; 2010 Mar;162(3):611-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments.
  • BACKGROUND: Accurate assessment of the somatic mutational status of clonal immunoglobulin variable region (IgV) genes is relevant in elucidating tumour cell origin in B-cell lymphoma; virgin B cells bear unmutated IgV genes, while germinal centre and postfollicular B cells carry mutated IgV genes.
  • Furthermore, biases in the IgV repertoire and distribution pattern of somatic mutations indicate a possible antigen role in the pathogenesis of B-cell malignancies.
  • OBJECTIVES: This work investigates the cellular origin and antigenic selection in primary cutaneous B-cell lymphoma (PCBCL).
  • METHODS: We analysed the nucleotide sequence of clonal IgV heavy-chain gene (IgVH) rearrangements in 51 cases of PCBCL (25 follicle centre, 19 marginal zone and seven diffuse large B-cell lymphoma, leg-type) and compared IgVH sequences with their closest germline segment in the GenBank database.
  • CONCLUSIONS: Data indicate that neoplastic B cells of PBCBL have experienced germinal centre reaction and also suggest that the involvement of IgVH genes is not entirely random in PCBCL and that common antigen epitopes could be pathologically relevant in cutaneous lymphomagenesis.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, B-Cell / genetics. Skin Neoplasms / genetics. Somatic Hypermutation, Immunoglobulin / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906071.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region
  •  go-up   go-down


24. Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Rizzi S, Rattotti S, Rumi E, Pascutto C, Vetro A, Astori C, Boveri E, Lucioni M, Paulli M, Zuffardi O, Lazzarino M: High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Hum Pathol; 2009 Nov;40(11):1628-37
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma.
  • Splenic marginal zone B-cell lymphoma is characterized by high genetic heterogeneity, and hepatitis C virus infection seems to be involved in a subset of patients.
  • Genome-wide array comparative genomic hybridization at a 100-kilobase (kb) resolution was performed in 34 patients with splenic marginal zone B-cell lymphoma, 12 of whom were hepatitis C virus positive.
  • The high-risk group identified according to the new splenic marginal zone B-cell lymphoma prognostic score was associated with del(7q) (P = .01) and del(17p) (P = .02).
  • Hepatitis C virus-positive splenic marginal zone B-cell lymphoma patients have no specific chromosome alterations.
  • [MeSH-major] Comparative Genomic Hybridization. Genome-Wide Association Study. Hepatitis C / complications. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647853.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


25. Topalkara A, Ben-Arie-Weintrob Y, Ferry JA, Foster CS: Conjunctival marginal zone B-cell lymphoma (MALT lymphoma) with amyloid and relapse in the stomach. Ocul Immunol Inflamm; 2007 Jul-Aug;15(4):347-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival marginal zone B-cell lymphoma (MALT lymphoma) with amyloid and relapse in the stomach.
  • The authors report a localized (primary) conjunctival marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue (MALT)-type), with amyloid deposition with relapse in the stomach, 14 months after the initial diagnosis.
  • Ocular adnexal marginal zone B-cell MALT lymphoma is often localized at diagnosis; some relapse in typical MALT sites.
  • There are few reports of localized conjunctival lymphoma with a relapse in the stomach.
  • The authors suggest that all patients with localized ocular adnexal lymphoma be followed for an extended period.
  • [MeSH-major] Amyloid / metabolism. Amyloidosis / pathology. Conjunctival Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763134.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid; 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Martin MG, Cashen AF: SEER analysis of subcutaneous panniculitis-like T-cell lymphoma (SPTL). J Clin Oncol; 2009 May 20;27(15_suppl):e19527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SEER analysis of subcutaneous panniculitis-like T-cell lymphoma (SPTL).
  • : e19527 Background: The uncommon nature of SPTL has hampered its clinical characterization.
  • Cases of SPTL were defined by the ICD-O-3 code 9708.
  • We also analyzed outcomes for patients < and ≥ 50y at diagnosis.
  • 5-year lymphoma specific survival was 51%; 5-year OS was 41%.
  • Lymphoma specific survival was also significantly longer in the younger patients (G-B-W p=0.0015).
  • This result suggests a different biology between younger and older patients with SPTCL, possibly because the AB- subtype is more prevalent in younger patients, as reported by the EORTC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pandya VB, Conway RM, Taylor SF: Primary cutaneous B cell lymphoma presenting as recurrent eyelid swelling. Clin Exp Ophthalmol; 2008 Oct;36(7):672-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B cell lymphoma presenting as recurrent eyelid swelling.
  • Primary cutaneous lymphoma represents a distinct clinical entity within the spectrum of haematological malignancy.
  • A case of primary cutaneous B cell lymphoma is reported, presenting in an 87-year-old female with a 2-year history of intermittent swelling and discolouration of the right upper and lower eyelids, in the absence of systemic symptoms.
  • Histopathological examination of an incision biopsy revealed a lymphoid infiltrate in the dermis with immunophenotypic features of B cell lymphoma.
  • Staging investigations confirmed the absence of systemic disease.
  • Ophthalmologists should include primary cutaneous lymphoma in the differential diagnosis of recurrent eyelid swelling.
  • [MeSH-major] Edema / pathology. Eyelid Neoplasms / pathology. Eyelids / pathology. Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983553.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • The PI3K p110δ isoform is highly expressed in cells of hematopoietic origin and plays a key role in B cell maturation and function.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Cummings TJ, Stenzel TT, Klintworth G, Jaffe GJ: Primary intraocular T-cell-rich large B-cell lymphoma. Arch Pathol Lab Med; 2005 Aug;129(8):1050-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraocular T-cell-rich large B-cell lymphoma.
  • We report a primary intraocular T-cell-rich large B-cell lymphoma in a 57-year-old woman who underwent 3 diagnostic vitrectomies for a presumed diagnosis of panuveitis.
  • Histopathologic and immunohistochemical studies on the enucleated globe disclosed a primary intraocular large B-cell lymphoma involving the choroid, vitreous, and retina.
  • A large population of T cells was identified among the neoplastic B-cell population.
  • B-cell immunoglobulin gene rearrangement and T-cell receptor gene rearrangement studies using the polymerase chain reaction method indicated that a monoclonal immunoglobulin kappa light chain population was present and that the T-cell population was not monoclonal.
  • This case highlights the importance of interpreting cytologic features in vitreous aspirates in the context of the clinical situation.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Clone Cells. DNA, Neoplasm / analysis. Eye Enucleation. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048400.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


30. van Galen JC, Hoefnagel JJ, Vermeer MH, Willemze R, Dijkman R, Tensen CP, de Boer WP, Meijer CJ, Oudejans JJ: Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma. J Pathol; 2008 Jul;215(3):340-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma.
  • Two distinct primary cutaneous large B cell lymphomas are recognized: primary cutaneous follicle centre lymphoma (PCFCL), characterized by an excellent prognosis, and primary cutaneous large B cell lymphoma, leg-type (PCLBCL leg-type), with an unfavourable prognosis.
  • To determine whether inhibition of the apoptosis pathways may underlie the difference in clinical outcome between PCFCL and PCLBCL leg-type, we investigated the expression of only apoptosis-related genes by microarray expression profiling.
  • Unsupervised cluster analysis was carried out using 169 genes involved in apoptosis on a group of 21 previously untreated patients diagnosed with primary cutaneous large B cell lymphoma.
  • Cluster analysis resulted in two separate groups which showed large overlap with the PCFCL and PCLBCL leg-type.
  • Thus, strategies neutralizing the function of apoptosis-inhibiting proteins might be effective in PCLBCL leg-type.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / genetics. Neoplasms, Multiple Primary / genetics. Oligonucleotide Array Sequence Analysis. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland.
  • (PMID = 18498125.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Brusamolino E, Maffioli M, Bonfichi M, Vitolo U: Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. Future Oncol; 2008 Apr;4(2):199-210
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.
  • The field of treatment of diffuse large B-cell lymphoma has been in a continuous flux over the last 10-15 years owing to the introduction of new therapeutic approaches such as dose-dense chemotherapy, monoclonal antibodies and high-dose chemotherapy followed by autologous peripheral blood stem cell transplant.
  • The use of clinical prognostic factors has improved our ability to predict the outcome of these lymphomas; moreover, the gene and protein expression pattern has been shown, at least in the pre-rituximab era, to be an independent and powerful prognostic indicator.
  • This review will focus on results obtained in the last decade by large clinical trials evaluating the first-line therapy in nonlocalized diffuse large B-cell lymphoma; special emphasis will be placed on more mature results that can be indicated as 'standard' therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Gene Expression Profiling. Humans. Immunochemistry. Middle Aged. Positron-Emission Tomography. Predictive Value of Tests. Prognosis. Rituximab. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407733.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 64
  •  go-up   go-down


32. Wang J, Sun NC, Chen YY, Weiss LM: T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):109-15
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases.
  • T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), a proliferating peripheral B-cell neoplasm, is a morphologic variant of diffuse large B-cell lymphoma (DLBCL), which may be confused with Hodgkin's lymphoma, non-Hodgkin's lymphoma, and reactive lymphadenopathies.
  • Though more recent studies suggested that it might be a distinct clinicopathologic entity and/or a heterogeneous entity with derivation from germinal center B cells, its histogenetic derivation remains controversial.
  • The authors analyzed 30 cases of THRLBCL to further characterize the origin of the neoplastic cells using immunohistochemical and molecular studies for expression of Bcl-6, CD10, and CD138, as well as rearrangements of IgH/bcl-2 genes on paraffin-embedded tissue.
  • Half of the cases (15/30) showed Bcl-6 expression and five cases (19%) showed CD10 expression, but none had CD138 expression (0/20).
  • Only three cases showed coexpression of both Bcl-6 and CD10.
  • Molecular studies performed in 21 cases detected rearrangement of immunoglobulin heavy gene in 18 cases, with none having detectable Bcl-2 gene rearrangement.
  • These data indicate that similar to DLBCL, the cell origin of neoplastic cells in THRLBCL is composed of a heterogeneous group of proliferating peripheral B cells, with only some cases originating from germinal center B cells and others derived from heterogeneous origins.
  • Lack of Bcl-2 gene rearrangements seems to argue against a possible progression from preexisting follicular lymphoma.
  • Thus, the normal counterpart of the neoplastic cells cannot at this time be the sole basis for the subclassification of THRLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894921.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


33. Wilson KS: Regression of follicular lymphoma with alternative therapy using Devil's Claw (DC); Coincidence or causation? J Clin Oncol; 2009 May 20;27(15_suppl):e19560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of follicular lymphoma with alternative therapy using Devil's Claw (DC); Coincidence or causation?
  • Two follicular lymphoma (FL) pts who had objective tumor regression after taking the herb DC without cytotoxic therapy are reported here.
  • In January 2000, pt #1 presented with co-existent IgG plasma cell dyscrasia and stage 3A grade 2 FL with 5 cm cervical and R/P nodes.
  • He developed overt myeloma in Aug 2001, when he stopped DC/Essiac and received HDCT/ASCT following which there has been no clinical progression of lymphoma.
  • He learned of pt #1 through the local Lymphoma Patient Support Group and started DC alone.
  • COX-2 inhibition has an accepted role in cancer prevention (Steinbach et al, NEJM 2000), has been implicated in lymphomagenesis (Wun et al, Leuk Res 2004) and associated with both stage of lymphoma and response to standard treatment (Hazar et al, Leuk Lymphoma 2004).
  • However, spontaneous regression in low grade lymphoma has been reported in 7 of 44 pts on observation only (Krikorian et al, 1980); none were on herbal medications or COX-2 inhibitors.
  • The key issue in both these patients is whether or not the disease regression was "spontaneous" or causally related to DC therapy, but the timing of response suggests a potential therapeutic benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Rittenbach J, Cao JD, Weiss LM, Rowsell EH, Chick W, Wang J: Primary diffuse large B-cell lymphoma of the uterus presenting solely as an endometrial polyp. Int J Gynecol Pathol; 2005 Oct;24(4):347-51
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the uterus presenting solely as an endometrial polyp.
  • We report a primary diffuse large B-cell lymphoma of endometrial polyp in a 44-year-old woman who presented with irregular vaginal spotting and was found to have a polyp protruding from the cervical os.
  • Histology of the polyp showed an atypical diffuse infiltration by large, mononuclear cells within the stroma and between endometrial glands in one of the polypoid fragments.
  • Immunohistochemistry and testing for immunoglobulin heavy chain gene rearrangement showed a B-cell lineage, consistent with diffuse large B-cell lymphoma.
  • Staging procedures including detailed gynecology examination, body computed tomography scan, and bone marrow examination, as well as total hysterectomy, showed no evidence of lymphoma outside of the polyp.
  • To our knowledge, this represents the first well-documented instance of primary lymphoma of the uterus presenting as an endometrial polyp.
  • The differential diagnosis of endometrial biopsies containing an atypical lymphoid infiltrate should include the rather rare possibility of primary uterine lymphoma arising in an endometrial polyp.
  • Immunohistochemistry and/or molecular analysis for antigen receptor gene rearrangements are critical in arriving at the correct diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Polyps / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Bone Marrow / pathology. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Hysterectomy. Immunohistochemistry. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175080.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Bathelier E, Thomas L, Balme B, Coiffier B, Berger F, Ffrench M, Salles G, Dalle S: [Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases]. Ann Dermatol Venereol; 2008 Nov;135(11):748-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases].
  • [Transliterated title] Lymphome cutané de la zone marginale : étude histologique et immunophénotypique de 49 cas.
  • BACKGROUND: No histological or clinical criteria allow distinction between primary cutaneous marginal zone B-cell lymphoma (MZL) and secondary cutaneous forms of systemic marginal zone B-cell lymphoma.
  • Consequently, staging alone can indicate the origin of lymphoma.
  • Lymphoma is considered as primary cutaneous only if no other extracutaneous sites are found.
  • We studied the histological appearance of 49 cutaneous lymphomas in order to find distinctive criteria indicative of an extracutaneous origin.
  • MATERIALS AND METHODS: This was a retrospective descriptive study of histological appearance for 49 patients with cutaneous marginal lymphoma: 29 cases of the primary form and 20 cases with extracutaneous involvement.
  • DISCUSSION: A cutaneous tropism of primary MZL suggested the hypothesis of specific cutaneous receptors on B-cells that could have led to different histological appearances depending on the origin of the lymphoma.
  • [MeSH-major] Gene Rearrangement. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Phenotype. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061653.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O, Groupe d'Etude des Lymphomes de l'Adulte Programs: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol; 2006 Feb 20;24(6):953-60
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
  • PURPOSE: Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL).
  • Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate.
  • PATIENTS AND METHODS: We studied the HCV-positive patients with B-cell DLCL included in the Groupe d'Etude des Lymphomes de l'Adulte (GELA) programs LNH 93 and LNH 98.
  • RESULTS: Histologic types of HCV-positive DLCL were more frequently transformed from low-grade lymphoma than DLCL in HCV-negative patients (32% v 6%, P = .02).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatitis C / complications. Hepatitis C Antigens / blood. Liver / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Seroepidemiologic Studies. Severity of Illness Index. Spleen / pathology. Spleen / virology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jul 20;24(21):3513; author reply 3513-4 [16849775.001]
  • (PMID = 16418500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis C Antigens
  •  go-up   go-down


37. Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H: Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res; 2006 Apr 15;66(8):4496-502
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
  • The immunoglobulin receptor of B-cell lymphomas constitutes a specific tumor antigen (idiotype) and a target for active immunotherapy.
  • Encouraging results have been reported in phase II trials after s.c. vaccination of follicular lymphoma patients during clinical remission with idiotype produced from eukaryotic cell lines and coupled to an immunogenic carrier macromolecule.
  • Patients (n = 18) with advanced B-cell malignancies received repetitive intradermal vaccinations with 0.5 to 1.65 mg recombinant idiotype Fab fragment mixed with lipid-based adjuvant in combination with 150 mug granulocyte macrophage colony-stimulating factor s.c. at the same location.
  • Of 17 evaluable patients, five developed specific anti-vaccine antibodies, and eight developed anti-Fab T-cell responses.
  • T-cell reactivity was independent of the cellular immune status and was idiotype specific as shown by statistical regression analysis (P = 0.0024) and epitope mapping studies.
  • Intradermal administration of uncoupled recombinant idiotype with appropriate adjuvants may overcome profound clinical immunosuppression and induce specific immune responses.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. Vaccination / methods

  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618777.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Epitopes, T-Lymphocyte; 0 / Immunoglobulin Idiotypes
  •  go-up   go-down


38. Beltran BE, Morales D, Quiñones P, Salas R, Castillo J: Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma.
  • : 8575 Background: Adult T-cell leukemia/lymphoma (ATLL) is associated with human T-cell lymphotropic virus type-I (HTLV-1) described in Southern Japan, Europe, Caribbean and South America.
  • Diagnosis was based on clinical history and histological findings consistent with ATLL and either positive HTLV-1 serology or evidence of HTLV-1 integration.
  • Clinical types were acute (n=45), lymphomatous (n=43), cutaneous (n=10), smoldering (n=3) and chronic (n=1).
  • Median OS for acute, lymphomatous, smoldering and cutaneous subtype were 2, 11, 17 and 39 months, respectively (log-rank 28.5, p<0.00001).
  • In the univariate analysis, presence of B symptoms, ECOG performance status 2, clinical stage II or higher, elevated LDH level and bone marrow (BM) involvement were independent factors for survival with p<0.05.
  • The prognostic index for T-cell lymphoma (PIT) score was determined in 80 patients; 20 (25%), 17 (21%), 33 (41%) and 10 (13%) patients had scores of 0-1, 2, 3 and 4, respectively.
  • CONCLUSIONS: This retrospective series represents the largest Latin-American experience on ATLL, which is a heterogeneous disease with distinct clinical features and outcomes.
  • The IPI ant PIT scores, used for risk-stratification of aggressive B-cell and peripheral T-cell lymphomas, respectively, appear as good prognostic indicators for ATLL as well.
  • Further research is needed to better risk-stratify this unique lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, Uike N, Eto T, Ohshima K, Suzumiya J: Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. J Clin Exp Hematop; 2009 May;49(1):1-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma.
  • CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) therapy achieves a response in more than 60% patients with diffuse large B-cell lymphomas (DLBCLs).
  • [MeSH-major] Anthracyclines / pharmacology. Antigens, Neoplasm / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Lymphoma, Large B-Cell, Diffuse / drug therapy. Oncogenes. Predictive Value of Tests
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / pharmacology. Antibiotics, Antineoplastic / therapeutic use. Biomarkers, Tumor. Disease-Free Survival. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474511.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human
  •  go-up   go-down


40. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA: FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3265-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
  • PURPOSE: Large B-cell lymphomas (LBCL) arise from normal antigen-exposed B cells at germinal center (GC) or post-GC stages of differentiation.
  • Negative selection of normal low-affinity or self-reactive GC B-cells depends on CD95 (FAS)-mediated apoptosis.
  • Herein, we ask whether FAS death domain mutations and NFkappaB-mediated overexpression of cFLIP represent alternative mechanisms for deregulating the extrinsic apoptotic pathway in LBCL subtypes defined by gene expression profiling [oxidative phosphorylation, B-cell receptor/proliferation, and host response diffuse LBCLs and primary mediastinal LBCLs].
  • EXPERIMENTAL DESIGN: The FAS receptor was sequenced, FAS death domain mutations identified, and cFLIP expression assessed in a series of primary LBCLs with gene expression profiling-defined subtype designations and additional genetic analyses [t(14;18) and t(3;v)].
  • RESULTS: FAS death domain deletions were significantly more common in oxidative phosphorylation tumors, which also have more frequent t(14;18), implicating structural abnormalities of either the extrinsic or intrinsic pathway in this diffuse LBCL subtype.
  • CONCLUSIONS: These data suggest that the gene expression profiling-defined LBCL subtypes have different mechanisms for deregulating FAS-mediated cell death and, more generally, that these tumor groups differ with respect to their underlying genetic abnormalities.
  • [MeSH-major] Antigens, CD95 / genetics. Apoptosis / immunology. CASP8 and FADD-Like Apoptosis Regulating Protein / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. DNA Mutational Analysis / methods. Down-Regulation / immunology. Gene Expression Profiling. Humans. NF-kappa B / metabolism. Point Mutation. Protein Structure, Tertiary / genetics. Proto-Oncogene Proteins c-bcl-2 / immunology. Proto-Oncogene Proteins c-bcl-6 / immunology. Reverse Transcriptase Polymerase Chain Reaction / methods. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740746.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


41. Ghisolfi L, Calastretti A, Franzi S, Canti G, Donnini M, Capaccioli S, Nicolin A, Bevilacqua A: B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. J Biol Chem; 2009 Jul 31;284(31):20946-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity.
  • Here we focused on the post-transcriptional regulation of bcl-2 mRNA in human cell lines under different conditions and genetic backgrounds.
  • In the context of an AUBPs silencing approach, HuR knockdown reduced the expression of endogenous bcl-2, whereas unexpectedly, a bcl-2 ARE-reporter transcript increased significantly, suggesting that HuR expression has opposite effects on endogenous and ectopic bcl-2 ARE.
  • Moreover, evidence was provided for the essential, specific and dose-dependent role of the Bcl-2 protein in regulating the decay kinetics of its own mRNA, as ascertained by a luciferase reporter system.
  • Altogether, the data support a model whereby the Bcl-2 protein is the major determinant of its own ARE-dependent transcript half-life in living cells and its effect overcomes the activity of ARE-binding proteins.
  • [MeSH-major] Antigens, Surface / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. RNA-Binding Proteins / metabolism. Regulatory Sequences, Ribonucleic Acid / genetics
  • [MeSH-minor] Cell Line. Clone Cells. ELAV Proteins. ELAV-Like Protein 1. Gene Silencing. Genes, Reporter. Heterogeneous-Nuclear Ribonucleoprotein D / metabolism. Humans. Immunoprecipitation. Luciferases / metabolism. Poly(A)-Binding Proteins / metabolism. RNA Stability. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Transfection

  • COS Scholar Universe. author profiles.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2001 Feb;58(2):266-77 [11289308.001]
  • [Cites] Oncogene. 2008 Oct 16;27(47):6151-63 [18641687.001]
  • [Cites] Mol Cells. 2002 Dec 31;14(3):323-31 [12521293.001]
  • [Cites] J Cell Physiol. 2003 Jun;195(3):356-72 [12704645.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23451-9 [12702730.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1279-88 [14976220.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):189-203 [14996503.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49 [14996506.001]
  • [Cites] Mol Cell. 2004 Jun 4;14(5):571-83 [15175153.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7263-71 [15187101.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32393-400 [15187092.001]
  • [Cites] Trends Genet. 2004 Oct;20(10):491-7 [15363903.001]
  • [Cites] Biol Cell. 2004 Sep;96(7):479-98 [15380615.001]
  • [Cites] Nature. 1988 Nov 17;336(6196):259-61 [2848196.001]
  • [Cites] Genomics. 1998 Mar 1;48(2):195-202 [9521873.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):34970-5 [9857028.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29831-7 [10514462.001]
  • [Cites] Cell. 2005 Mar 11;120(5):623-34 [15766526.001]
  • [Cites] Mol Pharmacol. 2005 Sep;68(3):816-21 [15955869.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34609-16 [16109718.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9520-31 [16227602.001]
  • [Cites] Biochem Soc Trans. 2006 Feb;34(Pt 1):30-4 [16246172.001]
  • [Cites] Nucleic Acids Res. 2005;33(22):7138-50 [16391004.001]
  • [Cites] Curr Dir Autoimmun. 2006;9:74-94 [16394656.001]
  • [Cites] Mol Endocrinol. 2006 Apr;20(4):916-30 [16306087.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):3295-307 [16581801.001]
  • [Cites] Mol Pharmacol. 2007 Feb;71(2):531-8 [17077270.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] FEBS J. 2007 Feb;274(3):867-78 [17288565.001]
  • [Cites] Pharmacol Ther. 2007 Apr;114(1):56-73 [17320967.001]
  • [Cites] Cell Cycle. 2007 Jun 1;6(11):1288-92 [17534146.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):533-43 [17572691.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19958-68 [17470429.001]
  • [Cites] J Biomed Sci. 2007 Jul;14(4):523-32 [17514363.001]
  • [Cites] Exp Cell Res. 2007 Aug 1;313(13):2937-45 [17512931.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(18):6265-78 [17620417.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30070-7 [17711853.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):498-508 [17989353.001]
  • [Cites] BMC Mol Biol. 2007;8:111 [18053171.001]
  • [Cites] EMBO J. 2008 Feb 6;27(3):471-81 [18256698.001]
  • [Cites] Trends Biochem Sci. 2008 Mar;33(3):141-50 [18291657.001]
  • [Cites] J Cell Biol. 2008 Apr 21;181(2):189-94 [18411313.001]
  • [Cites] Mol Syst Biol. 2008;4:190 [18463614.001]
  • [Cites] Autophagy. 2008 Jul;4(5):600-6 [18497563.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4180-8 [18757333.001]
  • [Cites] Neurochem Res. 2002 Oct;27(10):957-80 [12462398.001]
  • (PMID = 19520857.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Heterogeneous-Nuclear Ribonucleoprotein D; 0 / Poly(A)-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Regulatory Sequences, Ribonucleic Acid; 0 / TIA1 protein, human; 0 / hnRNP D0; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2742860
  •  go-up   go-down


42. Hoffmann C, Repp R, Schoch R, Gahn B, Schub N, Beck C, Humpe A, Kneba M, Horst HA, Schmitz N, Gramatzki M: Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. Eur J Med Res; 2006 Feb 21;11(2):73-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma.
  • There is now evidence that the tolerability and response to systemic chemotherapy in HIV-infected patients with AIDS-related lymphoma (ARL) is significantly improved by highly active antiretroviral therapy.
  • Here we report an severely immunocompromised AIDS patient with recurrent ARL who was successfully treated with autologous stem cell transplantation (ASCT).
  • [MeSH-major] B-Lymphocytes / pathology. Hematopoietic Stem Cell Transplantation. Immunocompromised Host. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504964.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN: CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res; 2005 Jan 1;11(1):370-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
  • The CD20 B-cell differentiation antigen is an attractive target for immunotherapy of B-cell lymphomas.
  • In an experimental lymphoma model, BALB/c mice were immunized with mouse or human CD20 cDNA (mCD20 and hCD20, respectively) or their extracellular domains (minigenes).
  • IFNgamma secretion by CD8+ T cells against CD20 was detected in mice vaccinated with hCD20 or human minigene, indicating that hCD20-primed CD8+ T cells recognize syngeneic CD20.
  • Systemic challenge with syngeneic A20 cells, an aggressive lymphoma, resulted in long-term survival in a subset of immunized mice.
  • CD8+ T-cell depletion during the effector phase completely abrogated this effect.
  • Antibodies against a recombinant mouse CD20 protein produced in insect cells were detected in mice immunized with hCD20 DNA and human and mouse minigene, but not in mice receiving mCD20 DNA.
  • These results show that active immunization with xenogeneic DNA vaccines can induce CD8+ T cell-dependent immunity against CD20.
  • [MeSH-major] Antigens, CD20 / biosynthesis. CD8-Positive T-Lymphocytes / immunology. Immunotherapy / methods. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. Neoplasms / therapy. Vaccines, DNA
  • [MeSH-minor] Animals. Antibodies, Monoclonal / chemistry. Antigens, Neoplasm / immunology. Biolistics. Blotting, Western. CD4-Positive T-Lymphocytes / immunology. DNA, Complementary / metabolism. Enzyme-Linked Immunosorbent Assay. Epitopes / chemistry. Female. Humans. Insects. Interferon-gamma / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Peptides / chemistry. Plasmids / metabolism. Protein Structure, Tertiary. Recombinant Fusion Proteins / metabolism. Recombinant Proteins / chemistry. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 33049; United States / NCI NIH HHS / CA / CA58621; United States / NCI NIH HHS / CA / P01 CA23766; United States / NCI NIH HHS / CA / R01 CA55349
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / Epitopes; 0 / Peptides; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / Vaccines, DNA; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


44. Pop IV, Pop LM, Ghetie MA, Vitetta ES: Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines. Leuk Lymphoma; 2009 Jul;50(7):1155-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines.
  • Previous studies have shown that rapamycin can inhibit the growth of several different types of human tumor cells in vitro.
  • In certain cases, it can reverse the phenotype of multidrug resistant (MDR) cells.
  • However, there is limited information concerning its effect on P-glycoprotein (P-gp), a pump that is responsible for chemoresistance in many MDR cells.
  • We investigated the effect of rapamycin on both P-gp function and the MDR phenotype in four cell lines.
  • One cell line was also xenografted into SCID mice to determine whether rapamycin would chemosensitize the cells in vivo.
  • Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.
  • We demonstrated that it inhibited the growth of the three cell lines in vitro and one in vivo showing that it modulated both the expression and function of P-gp and chemosensitized the three cell lines as effectively as verapamil.
  • [MeSH-major] Down-Regulation. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. P-Glycoprotein / metabolism. Protein Kinases / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, SCID. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Jul;50(7):1065-6 [19557625.001]
  • (PMID = 19557637.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-104026
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


45. Cha SC, Kwak LW, Ruffini PA, Qin H, Neelapu S, Biragyn A: Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J Immunol Methods; 2006 May 30;312(1-2):79-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.
  • Active immunization of follicular lymphoma patients with idiotypic vaccines elicits antigen-specific antibody responses, T-cell responses, and antitumor effects.
  • To identify potential antigens, a phage surface expressed cDNA library derived from primary tumor cells was screened with sera from idiotype-vaccinated patients.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antigens, Neoplasm / genetics. Cloning, Molecular / methods. Gene Library. Lymphoma, B-Cell / immunology. Peptide Library
  • [MeSH-minor] Amino Acid Sequence. Cancer Vaccines / immunology. DNA, Complementary / genetics. GTP-Binding Proteins / genetics. GTP-Binding Proteins / immunology. Humans. Immune Sera / immunology. Immunoglobulin Idiotypes / immunology. Lymphoma, Follicular / immunology. Molecular Sequence Data. Peptides / genetics. Peptides / immunology. Ribonucleoprotein, U1 Small Nuclear / genetics. Ribonucleoprotein, U1 Small Nuclear / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9437-42 [10931945.001]
  • [Cites] J Exp Med. 1997 Aug 29;186(5):785-93 [9271594.001]
  • [Cites] J Exp Med. 2001 Nov 5;194(9):1313-23 [11696596.001]
  • [Cites] J Intern Med. 2001 Dec;250(6):462-75 [11902815.001]
  • [Cites] J Immunol Methods. 2002 May 1;263(1-2):123-32 [12009209.001]
  • [Cites] Cancer Immunol Immunother. 2002 Dec;51(11-12):655-62 [12439611.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):167-73 [12538465.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):998-1008 [12631598.001]
  • [Cites] J Clin Immunol. 2004 Sep;24(5):571-8 [15359116.001]
  • [Cites] Gene. 2004 Oct 27;341:291-304 [15474311.001]
  • [Cites] J Infect Dis. 1980 Oct;142(4):569-74 [6255043.001]
  • [Cites] EMBO J. 1986 Dec 1;5(12):3209-17 [3028775.001]
  • [Cites] Clin Immunol Immunopathol. 1990 Feb;54(2):266-80 [2104788.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):489-95 [8340755.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] J Immunol. 1996 Jun 1;156(11):4504-13 [8666827.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2501-8 [8676070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4031-5 [9834205.001]
  • [Cites] J Exp Med. 1999 May 17;189(10):1659-68 [10330445.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • [Cites] Trends Immunol. 2001 May;22(5):269-76 [11323286.001]
  • (PMID = 16631194.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000770-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / DNA, Complementary; 0 / GIMAP7 protein, human; 0 / Immune Sera; 0 / Immunoglobulin Idiotypes; 0 / Peptide Library; 0 / Peptides; 0 / Ribonucleoprotein, U1 Small Nuclear; 0 / SNRNP70 protein, human; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS51528; NLM/ PMC2431127
  •  go-up   go-down


46. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ: Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Int J Hematol; 2010 Oct;92(3):510-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
  • According to a previous review, multiple mucosa-associated lymphoid tissue (MALT)-organs involving marginal zone B cell lymphomas (MZLs) are present in 10-30% of patients.
  • However, the clinical features and specific relationships among involved organs are yet to be clearly identified.
  • In this study, we conducted retrospective analyses of multiple MALT organs involving MZLs (MM-MZLs) to identify their clinical features, treatment, prognosis, and specific relationships among involved organs.
  • MM-MZLs tend to be an indolent disease, characterized by prolonged survival with frequent relapses.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838958.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Zhao XF, Cherian S, Sargent R, Seethala R, Bonner H, Greenberg B, Bagg A: Expanded populations of surface membrane immunoglobulin light chain-negative B cells in lymph nodes are not always indicative of B-cell lymphoma. Am J Clin Pathol; 2005 Jul;124(1):143-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanded populations of surface membrane immunoglobulin light chain-negative B cells in lymph nodes are not always indicative of B-cell lymphoma.
  • Surface membrane immunoglobulin (SmIg) light chain restriction in B cells is especially helpful in documenting clonality, and the loss of SmIg by B cells in extramedullary sites also has been used as a criterion to support the presence of lymphoma.
  • However, we identified 3 cases of benign follicular hyperplasia (in 101 cases analyzed) with profound expansions (56%-88% of the B cells) of SmIg light chain-negative B cells without clonality by immunoglobulin heavy chain gene polymerase chain reaction.
  • Thus, although uncommonly encountered, lack of SmIg light chain expression by B cells should not necessarily be interpreted as indicative of lymphoma.
  • Interestingly, 2 of the 3 patients with these "aberrant" expansions were HIV+, and such patients are at heightened risk for the development of lymphoma.
  • Therefore, there is the potential for misdiagnosing lymphoma if flow cytometric data are interpreted inappropriately in isolation.
  • [MeSH-major] B-Lymphocytes / metabolism. Hyperplasia / diagnosis. Immunoglobulin Light Chains / metabolism. Lymphatic Diseases / diagnosis. Lymphoma, B-Cell / diagnosis. Receptors, Antigen, B-Cell / metabolism
  • [MeSH-minor] Adult. Clone Cells. Diagnosis, Differential. Female. Flow Cytometry. Humans. Immunophenotyping. Lymph Nodes / cytology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Polymerase Chain Reaction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923170.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


48. Pentheroudakis G, Goussia A, Voulgaris E, Nikolaidis K, Ioannidou E, Papoudou-Bai A, Grepi K, Kanavaros P, Pavlidis N, Bai M: High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. Leuk Lymphoma; 2010 Jul;51(7):1260-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.
  • The results were analyzed in relation to the expression of cell cycle proteins (Ki67, p53, HDM2, p21, p14, pRb, p16, and cyclins A, B1, D1, D2, D3, and E) and BCL6/CD10/MUM1/CD138 B-cell differentiation immunophenotype and outcome.
  • The TopoIIalpha expression showed significant positive correlations with the proliferation index Ki67 (p = 0.002), cell cycle proteins pRb and cyclin D2 (p = 0.018 and p = 0.028, respectively), and the germinal center proteins bcl6 and CD10 (p = 0.010 and p < 0.0001, respectively).
  • TopoIIalpha expression was significantly higher in germinal center B-cell like (GCB) DLBCL than in non-germinal center B-cell like (non-GCB) DLBCL (p = 0.048).
  • On multivariate analysis, only stage of disease retained independent prognostic significance (HR 0.33 for early stage, p = 0.008).
  • Although TopoIIa gene copy number abnormalities were not found in DLBCL, high levels of protein expression are associated with GCB-cell differentiation immunophenotype, high proliferation, and response to treatment.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Germinal Center / enzymology. Lymphoma, Large B-Cell, Diffuse / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Cycle Proteins / metabolism. Cell Differentiation. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Amplification. Humans. Immunoenzyme Techniques. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Prednisolone / therapeutic use. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / therapeutic use


49. Cheng WW, Allen TM: Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release; 2008 Feb 18;126(1):50-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
  • As part of an ongoing effort to develop a clinically acceptable doxorubicin formulation, targeted against B-cell malignancies, this study compared long-circulating (Stealth) immunoliposomes (SIL) that were targeted against the B-cell antigen CD19, via a whole HD37 monoclonal antibody (HD37 mAb), versus its Fab' fragment (HD37 Fab') or an HD37-c-myc-Cys-His5 single chain Fv fragment (scFv, HD37-CCH) directed against the same epitope.
  • Compared to untargeted liposomes (SL), SIL showed increased binding in vitro to CD19-expressing Raji cells and, when loaded with doxorubicin (SIL-DXR), increased cytotoxicity against Raji (CD19(+)), but not Molt4 (CD19(-)) cells.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal. Antigens, CD19 / immunology. Burkitt Lymphoma / metabolism. Doxorubicin / administration & dosage. Immunoglobulin Fab Fragments
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line, Tumor. Cell Survival / drug effects. Female. Humans. Liposomes. Mice. Mice, Inbred BALB C. Mice, SCID. Nanoparticles. Neoplasm Transplantation. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068849.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Immunoglobulin Fab Fragments; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


50. Copur MS, Deshpande A, Mleczko K, Norvell M, Hrnicek GJ, Woodward S, Frankforter S, Mandolfo N, Fu K, Chan WC: Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Croat Med J; 2005 Jun;46(3):458-62
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
  • Primary cutaneous T- and B-cell lymphomas are a heterogeneous group of diseases with varied clinical presentations and prognosis.
  • The use of new molecular, histological, and clinical criteria has improved their recognition.
  • Cutaneous B-cell and T-cell lymphomas are seldom found together in the same patient.
  • Here we report a rare case of mycosis fungoides variant of a cutaneous T-cell lymphoma (CTCL) which later developed Epstein-Barr virus (EBV) associated cutaneous B-cell lymphoproliferative disorder.
  • Histopathology and immunophenotyping of her tumor from the right breast nodule revealed a T-cell lymphoma consistent with mycosis fungoides.
  • After progression of her mycosis fungoides with worsening diffuse skin lesions on this regimen, her treatments were changed to oral bexarotene with an initial partial response followed by stable disease.
  • Biopsy of these lesions revealed EBV-positive large- and medium-sized pleomorphic B-cells consistent with EBV-driven B-cell lymphoproliferative disorder.
  • Bexarotene treatment was continued for another year until the mycosis fungoides progressed and became wide spread causing her death four and a half years after the initial diagnosis.
  • The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage in the same patient and the complete clinical response of EBV-related B-cell cutaneous component to topical acyclovir makes this rare case particularly interesting.
  • [MeSH-major] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861527.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


51. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S: Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol; 2005 Mar;32(3):227-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study.
  • BACKGROUND: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics.
  • Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome.
  • In this study, we used a tissue microarray (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL).
  • METHODS: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation.
  • Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined.
  • RESULTS: Our results identify two subgroups of lymphomas.
  • The first group showed staining with bcl-6 and had an overall survival of 176 months (p = 0.003).
  • The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1.
  • Three of four patients with PCLBCL of the leg showed no staining with bcl-6.
  • CONCLUSIONS: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Skin Neoplasms / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701085.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Transcription Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


52. Renné C, Willenbrock K, Martin-Subero JI, Hinsch N, Döring C, Tiacci E, Klapper W, Möller P, Küppers R, Hansmann ML, Siebert R, Bräuninger A: High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia; 2007 Apr;21(4):780-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma.
  • Mediastinal large B-cell (MBL) and classical Hodgkin lymphoma (HL) have several pathogenic mechanisms in common.
  • Indeed, MBL and HL were the only B-cell lymphomas where elevated cellular phospho-tyrosine contents were typical features.
  • Three TKs, JAK2, RON and TIE1, not expressed in normal B cells, were each expressed in about 30% of MBL cases, and 75% of cases expressed at least one of the TKs.
  • Among the intracellular pathways frequently triggered by TKs, the PI3K/AKT pathway was activated in about 40% of MBLs and essential for survival of MBL cell lines, whereas the RAF/mitogen-activated protein kinase pathway seemed to be inhibited.
  • No activating mutations were detected in the three TKs in MBL cell lines and primary cases.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. Lymphoma, B-Cell / genetics. Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Enzyme Activation. Gene Expression Regulation, Enzymologic. Humans. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / genetics


53. Fujiwara A, Nagayama S, Amada S, Shimamoto T, Shimao Y, Hayashi T: Intravascular large B-cell lymphoma involving mainly the uterus: report of a case using liquid-based cytology of the endometrium. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):787-92
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma involving mainly the uterus: report of a case using liquid-based cytology of the endometrium.
  • BACKGROUND: Intravascular lymphoma is a rare subtype of extranodal lymphoma.
  • Most instances of the disease are of B-cell lineage.
  • Diagnosis is difficult because of its nonspecific clinical signs, and many cases are diagnosed at autopsy.
  • A cytologic smear of the endometrium by liquid-based cytology demonstrated malignant cells.
  • Based on the curettage material, the lesion was diagnosed as an undifferentiated malignant tumor.
  • Total abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic/paraaortic lymphadenectomy revealed widely scattered lymphoma cells of B-cell lineage mainly in the vascular lumina of the uterus, right ovary and lymph nodes.
  • CONCLUSION: The final histologic type was established on the basis of the surgical material of hysterectomy.
  • Diagnosis was difficult because of prominent cellular atypia and rare location of the tumor.
  • Immunocytochemical examination of liquid-based samples can lead to a correct diagnosis of malignant lymphoma, even at the stage of endometrial cytologic examination.
  • [MeSH-major] Cytological Techniques / methods. Endometrium / blood supply. Endometrium / pathology. Lymphoma, B-Cell / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Cell Aggregation. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Myometrium / pathology. Myometrium / ultrasonography. Ovary / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053541.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, Hart J, Lai R, Montoto S, Gribben JG, Lister TA, Fitzgibbon J: Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood; 2009 Apr 9;113(15):3553-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.
  • To investigate the cell of origin linking follicular (FL) and transformed (t-FL) lymphomas, we analyzed the somatic hypermutation (SHM) pattern of the variable region of the immunoglobulin heavy gene (IgH-VH) in 18 sequential FL/t-FL samples and a father (donor) and son (recipient), who developed FL and t-FL, after transplantation.
  • Genealogic trees showed a pattern compatible with a common progenitor cell (CPC) origin in 13 cases.
  • On the basis of the father/son model, this CPC must be long-lived, providing a possible explanation for the incurable nature of this disease.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Stem Cells / pathology
  • [MeSH-minor] Biopsy. Bone Marrow Transplantation. Clone Cells / immunology. Clone Cells / pathology. Germinal Center / pathology. Humans. Male. Somatic Hypermutation, Immunoglobulin


55. Dean R, Masci P, Pohlman B, Andresen S, Serafino S, Sobecks R, Kuczkowski E, Curtis J, Maciejewski J, Rybicki L, Kalaycio M, Hsi E, Theil K, Bolwell BJ: Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant; 2005 Dec;36(12):1049-52
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
  • Allograft dendritic cell (DC) content has been identified as a predictor of relapse and event-free survival after allogeneic bone marrow transplantation.
  • However, the prognostic importance of DCs has not been evaluated in the setting of autologous hematopoietic stem cell transplantation (HSCT).
  • We prospectively determined pre-transplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT.
  • Pre-transplant DCs were measured in the collected stem cell products and were therefore indicative of cell numbers infused directly into patients; post transplant analysis of DCs was performed on the peripheral blood of patients 6 weeks after the infusion of autologous stem cells.
  • Higher pre-transplant levels of DC1 cells and total DCs were significantly associated with improved survival.
  • [MeSH-major] Dendritic Cells / cytology. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Cell Proliferation. Cell Transplantation. Female. Flow Cytometry. Granulocyte Colony-Stimulating Factor / metabolism. Hematopoietic Stem Cell Mobilization. Humans. Lymphoma. Male. Middle Aged. Models, Statistical. Prognosis. Prospective Studies. Recurrence. Stem Cell Transplantation. Stem Cells / cytology. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247431.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


56. Zambrano E, Mejía-Mejía O, Bifulco C, Shin J, Reyes-Múgica M: Extranodal marginal zone B-cell lymphoma/maltoma of the lip in a child: case report and review of cutaneous lymphoid proliferations in childhood. Int J Surg Pathol; 2006 Apr;14(2):163-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal marginal zone B-cell lymphoma/maltoma of the lip in a child: case report and review of cutaneous lymphoid proliferations in childhood.
  • All forms of cutaneous lymphomas are rare in children.
  • Extranodal marginal zone B-cell lymphomas (EMZBL)/mucosa-associated lymphoid tissue (MALT) lymphomas are unusual neoplasms in children and young adults.
  • We report a case of an EMZBL/MALT lymphoma of the lip in a previously healthy 14-year-old boy without immunodeficiency, confirmed by immunohistochemistry and documentation of clonal rearrangement of the immunoglobulin heavy-chain gene.
  • Additionally, we present a review of the differential diagnosis of skin and mucosal lymphoid proliferations in childhood.
  • [MeSH-major] Lip Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunohistochemistry. Male. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703182.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, Dang NH: Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res; 2005 Mar 1;65(5):1973-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
  • CD26 is a Mr 110,000 surface-bound glycoprotein with diverse functional properties, including having a key role in normal T-cell physiology and the development of certain cancers.
  • In this article, we show that surface expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results in enhanced topoisomerase IIalpha level in the B-cell line Jiyoye and subsequent in vitro sensitivity to doxorubicin-induced apoptosis.
  • Besides demonstrating that CD26 effect on topoisomerase IIalpha and doxorubicin sensitivity is applicable to cell lines of both B-cell and T-cell lineages, the potential clinical implication of our work lies with the fact that we now show for the first time that our in vitro results can be extended to a severe combined immunodeficient mouse model.
  • Our findings that CD26 expression can be an in vivo marker of tumor sensitivity to doxorubicin treatment may lead to future treatment strategies targeting CD26/DPPIV for selected human cancers in the clinical setting.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. DNA Topoisomerases, Type II / metabolism. Dipeptidyl Peptidase 4 / metabolism. Doxorubicin / pharmacology. Lymphoma, B-Cell / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Annexin A5 / metabolism. Antigens, Differentiation / metabolism. Antigens, Neoplasm. Apoptosis / drug effects. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Humans. In Vitro Techniques. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. MAP Kinase Kinase 3 / metabolism. MAP Kinase Kinase 6 / metabolism. Membrane Glycoproteins / metabolism. Mice. Mice, SCID. Neural Cell Adhesion Molecule L1 / metabolism. Phosphorylation / drug effects. RNA, Small Interfering / pharmacology. Receptors, Immunologic / metabolism. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753397.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antibiotics, Antineoplastic; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Membrane Glycoproteins; 0 / Neural Cell Adhesion Molecule L1; 0 / RNA, Small Interfering; 0 / Receptors, Immunologic; 80168379AG / Doxorubicin; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 3; EC 2.7.12.2 / MAP Kinase Kinase 6; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


58. Yousuf MY, Imran F, Davis A: A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy.
  • Investigations ruled out protein loss from the kidney and there was no evidence of chronic liver disease.
  • Protein-losing enteropathy became a diagnosis of exclusion.
  • Biopsies confirmed this to be grade II follicular non-Hodgkin lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Aug 18;24(35):5521-4 [16007185.001]
  • [Cites] Cell. 1999 Oct 15;99(2):143-53 [10535733.001]
  • [Cites] S Afr Med J. 1980 Jun 14;57(24):1009-11 [7404069.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Aug;90(2):124-5 [10936828.001]
  • [Cites] South Med J. 1975 Mar;68(3):354-7 [1173007.001]
  • [Cites] Trends Mol Med. 2002 Mar;8(3):133-9 [11879774.001]
  • [Cites] Am J Med Genet. 2002 Oct 15;112(3):284-90 [12357472.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]
  • [Cites] J Pathol. 2005 Jul;206(3):337-45 [15887287.001]
  • [Cites] Postgrad Med J. 1988 Apr;64(750):313-4 [3186577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8435-40 [16714381.001]
  • [Cites] Jpn J Clin Oncol. 1996 Aug;26(4):264-72 [8765187.001]
  • [Cites] Intern Med. 1997 Aug;36(8):556-60 [9260772.001]
  • [Cites] Z Gastroenterol. 1995 Apr;33(4):209-13 [7793120.001]
  • [Cites] J Dent Res. 2003 Jun;82(6):433-7 [12766194.001]
  • [Cites] Am J Med Genet A. 2003 Jul 30;120A(3):370-3 [12838557.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7 [15551738.001]
  • [Cites] Rinsho Ketsueki. 1989 Dec;30(12):2210-4 [2621805.001]
  • [Cites] Postgrad Med J. 1986 May;62(727):399-400 [3763551.001]
  • (PMID = 21686749.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028173
  •  go-up   go-down


59. Shi YK, Yang S, Han XH, Ma J, Ren HY, Cen XN, Zhou SY, Wang C, Jiang WQ, Huang HQ, Wang JM, Zhu J, Chen H, Han MZ, Huang H, Shen XM, Liu P, He XH: [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Aug;31(8):592-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
  • OBJECTIVE: To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL).
  • METHODS: Twenty-eight patients with aggressive B-cell NHL (22 newly diagnosed, 6 relapsed) were enrolled in this study.
  • Each patient received infusion of rituximab at a dose of 375 mg/m(2) for four times, on D1 before and on D7 of peripheral blood stem cell mobilization, and on D1 before and D8 after stem cell reinfusion.
  • CONCLUSION: These results suggest that adding rituximab to high-dose chemotherapy with peripheral blood stem cell transplantation is feasible and may be beneficial for patients with aggressive B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Fever / chemically induced. Fever / etiology. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Remission Induction. Rituximab. Survival Rate. Vincristine / adverse effects. Vincristine / therapeutic use. Vomiting / chemically induced. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021946.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; DICE protocol; EPOCH protocol; VAP-cyclo protocol
  •  go-up   go-down


60. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K: Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol; 2008 Jan;83(1):59-62
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
  • Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL).
  • In this study, we monitored serum HCV RNA levels and liver function in five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Hepatitis C / blood. Hepatitis C / genetics. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / immunology. RNA, Viral / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712791.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / RNA, Viral; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


61. Giri U, Terry NH, Kala SV, Lieberman MW, Story MD: Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28). Cancer Chemother Pharmacol; 2005 Jun;55(6):511-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
  • Responses vary depending on cell type, dose and the form of arsenic.
  • In this study, we investigated whether arsenic trioxide (As(2)O(3)) induces apoptosis in both chemosensitive and chemoresistant cell lines that varied in their expression of p28 (gsto1), the mouse homolog of GSTO1.
  • METHODS: The cytotoxicity of arsenic in the gsto1- and bcl-2-expressing chemoresistant and radioresistant LY-ar mouse lymphoma cell line, was compared with that of the LY-ar's parental cell line, LY-as.
  • LY-as cells are radiosensitive, apoptotically permissive, and do not express gsto1 or bcl-2.
  • Cell survival, glutathione (GSH) levels, mitochondrial membrane potential, and stress-activated kinase status after arsenic treatment were examined in these cell lines.
  • RESULTS: As(2)O(3) induced an equivalent dose- and time-dependent increase in apoptosis in these cell lines.
  • Cellular survival, as measured after a 24-h exposure, was also the same in each cell line.
  • With a prolonged exposure of As(2)O(3), both cell lines showed decreased activation of ERK family members, ERK1, ERK2 and ERK5.
  • As(2)O(3) enhanced the death signals in LY-ar cells through a decrease in GSH, loss of mitochondrial membrane potential, and abatement of survival signals.
  • This effect is similar to that seen when LY-ar cells are treated with thiol-depleting agents or by the removal of methionine and cysteine (GSH precursor) from the growth medium.
  • This response is also completely contrary to that seen for radiation, actinomycin D, VP-16 and other agents, where LY-ar cells do not succumb to apoptosis.
  • CONCLUSIONS: The overexpression of gsto1 in normally chemoresistant and radioresistant LY-ar cells renders them vulnerable to the cytotoxic effects of As(2)O(3), despite the 30-fold overexpression of the survival factor bcl-2.
  • Gsto1 and its human homolog, GSTO1, may serve as a marker for arsenic sensitivity, particularly in cells that are resistant to other chemotherapeutic agents.
  • [MeSH-major] Apoptosis / drug effects. Arsenicals / pharmacology. Drug Resistance, Neoplasm / drug effects. Glutathione Transferase / biosynthesis. Oxides / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Cloning, Molecular. Flow Cytometry. Glutathione / metabolism. Humans. Lymphoma, B-Cell / pathology. Membrane Potentials / drug effects. Mice. Mitochondria / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761769.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62209
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; EC 2.5.1.18 / GSTO1 protein, human; EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


62. Fietz T, Knauf WU, Hänel M, Franke A, Freund M, Thiel E, East German Study Group on Hematology and Oncology-OSHO: Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. Ann Hematol; 2009 May;88(5):433-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate.
  • Primary mediastinal large B cell lymphomas (MLCL) differ from other diffuse large cell lymphomas, leading to a description as a separate entity in the current World Health Organization classification.
  • No relapse occurred more than 2 years after diagnosis and initiation of treatment, but unfortunately, no patient with overt progression or relapse within these 2 years could be salvaged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Recurrence. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853160.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


63. De Meester J, Calvez R, Valitutti S, Dupré L: The Wiskott-Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets. J Leukoc Biol; 2010 Nov;88(5):1031-40
Genetic Alliance. consumer health - Wiskott Aldrich syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Wiskott-Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets.
  • WAS is a primary immunodeficiency as a result of mutations in the gene encoding the WASP, a key actin regulator of hematopoietic cells.
  • Although WAS CTLs killed target B cells in a SAg dose-dependent manner, their efficiency was reduced, especially at a low SAg dose.
  • The cytotoxic efficiency of WAS CTLs was particularly reduced against tumoral B cell lines.
  • WAS CTLs expressed normal levels of lytic molecules and demonstrated efficient exocytosis upon target cell encounter.
  • However, the lytic granules appeared not to fully polarize toward the center of the CTL/tumor target cell contact area.
  • [MeSH-minor] B-Lymphocytes / immunology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Cell Line. Cytokines / genetics. Cytokines / metabolism. Down-Regulation. Flow Cytometry. Humans. Interleukin-2 / immunology. Lymphocyte Activation / immunology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / immunology. Microscopy, Confocal. Receptors, Antigen, T-Cell / genetics. Tumor Necrosis Factor-alpha / immunology. Wiskott-Aldrich Syndrome / genetics. Wiskott-Aldrich Syndrome / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20689099.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Receptors, Antigen, T-Cell; 0 / Tumor Necrosis Factor-alpha; 0 / Wiskott-Aldrich Syndrome Protein
  •  go-up   go-down


64. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H: Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer; 2008 Sep 1;123(5):1181-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
  • Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell.
  • Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti-CD20 x anti-CD3), that connects B cells and T cells via its variable regions and recruits FcgammaRI(+) accessory immune cells via its Fc region.
  • Bi20 mediated efficient and specific lysis of B-cell lines and of B cells with low CD20 expression levels that were derived from CLL patients.
  • Remarkably, T-cell activation and tumor cell killing occurred in an entirely autologous setting without additional effector cells in 5 of 8 samples.
  • In comparison, rituximab, a chimeric monoclonal CD20 antibody, demonstrated a significantly lower B-cell eradication rate.
  • Additionally, Bi20, but not rituximab, upregulated the activation markers CD25 and CD69 on both CD4(+) and CD8(+) T cells in the presence of accessory immune cells.
  • CD14(+) accessory cells and the monocyte cell line THP-1 were activated via binding of the Fc region of Bi20, given that T cells were simultaneously engaged by the antibody.
  • In conclusion, Bi20 may offer new immunotherapeutic options for the treatment of B-cell lymphomas.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antibody-Dependent Cell Cytotoxicity / drug effects. Antigens, CD20 / immunology. Antigens, CD3 / immunology. Antineoplastic Agents / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Animals. Burkitt Lymphoma / drug therapy. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Isoelectric Focusing. Leukocytes, Mononuclear / drug effects. Lymphocyte Depletion. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546289.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antineoplastic Agents; 0 / Bi20 antibody
  •  go-up   go-down


65. Furlan A, Pietrogrande F, Marino F, Menin C, Polato G, Vianello F: Sequential development of large B cell lymphoma in a patient with peripheral T-cell lymphoma. Haematologica; 2008 Jan;93(1):e6-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential development of large B cell lymphoma in a patient with peripheral T-cell lymphoma.
  • Lymphomas of different histologic type can occur in the same patient.
  • Two types of lymphomas can be diagnosed in the same lymph node (composite lymphoma) or in different sites.
  • In the latter case, terms as simultaneous and sequential have been proposed to define the detection of two lymphomas at the same time or at different times, respectively.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. Neoplasms, Second Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166774.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Yanagawa N, Ogata SY, Motoyama T: Pulmonary localized AA type amyloidosis with cyst-like structures and marginal zone B-cell lymphoma of the MALT type coexisting independently in the left upper lung. Intern Med; 2008;47(17):1529-33
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary localized AA type amyloidosis with cyst-like structures and marginal zone B-cell lymphoma of the MALT type coexisting independently in the left upper lung.
  • The diagnosis of pulmonary mucosa-associated lymphoid tissue lymphoma was made.
  • The diagnosis of amyloidosis was confirmed by polarized light examination.
  • [MeSH-major] Amyloidosis / diagnosis. Cysts / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Amyloidosis AA.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758129.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Kojima M, Sugihara S, Iijima M, Ono T, Yoshizumi T, Masawa N: Marginal zone B-cell lymphoma of minor salivary gland representing tumor-forming amyloidosis of the oral cavity. A case report. J Oral Pathol Med; 2006 May;35(5):314-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-cell lymphoma of minor salivary gland representing tumor-forming amyloidosis of the oral cavity. A case report.
  • We report here a case of mucosa-associated lymphoid tissue (MALT)-type lymphoma arising from the minor salivary gland of the oral cavity exhibiting tumor-forming amyloidosis.
  • Despite multiple and multifocal recurrences including the lip, soft palate, tongue, oral base and vocal code and soft palate, the tumor remained localized in the upper aerodigestive tract, and the patient did not develop multiple myeloma during the course of disease.
  • Only the periphery of the lesion contained numerous plasmacytoid cells, along with occasional centrocyte-like cells.
  • The present case indicates that primary minor salivary gland MALT-type lymphoma appears to be the cause of tumor-forming amyloidosis of the upper aerodigestive tract including the larynx.
  • [MeSH-major] Amyloidosis / etiology. Laryngeal Diseases / etiology. Lymphoma, B-Cell, Marginal Zone / complications. Palate, Soft / pathology. Salivary Gland Neoplasms / complications. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630297.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


68. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C: Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer; 2009 Nov 15;115(22):5210-7
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
  • BACKGROUND: Currently, there are no consensus guidelines regarding the best therapeutic option for patients with extranodal marginal zone lymphomas of the mucosa-associated lymphoid tissue (MALT) type.
  • METHODS: Patients with systemically untreated or de novo extranodal MALT lymphoma received rituximab 375 mg/m(2) intravenously on Day 1 and fludarabine 25 mg/m(2) intravenously on Days 1 through 5 (Days 1-3 in patients aged >70 years) every 4 weeks, for 4 to 6 cycles.
  • RESULTS: Twenty-two patients were studied, including 12 patients with gastric lymphoma and 10 patients with extragastric MALT lymphoma.
  • Six patients (27%) had stage IV disease.
  • Primary extragastric disease was an adverse factor to achieve CR after 3 cycles of chemotherapy (hazard ratio, 23.3; 95% confidence interval, 2.0-273.3).
  • The progression-free survival rate at 2 years in patients with gastric and extragastric MALT lymphoma was 100% and 89%, respectively.
  • CONCLUSIONS: Combination therapy with rituximab and fludarabine is a very active treatment with favorable safety profile as first-line systemic treatment for patients with extranodal MALT lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Middle Aged. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672998.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


69. Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T: Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma; 2009 Aug;50(8):1301-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
  • Diffuse large B-cell lymphomas (DLBCLs) are a heterogeneous group of lymphomas, with no accepted biological prognostic markers in routine clinical practice.
  • Previously, matrix metalloproteinase (MMP-9), tissue inhibitors of matrix metalloproteinase (TIMP)- 1 and non-germinal center (GC) phenotype have been shown to associate with poor prognosis in DLBCL patients.
  • In this study, in patients treated with modern lymphoma treatments (5-year cause-specific survival 69.8%) MMP-2, MMP-9, TIMP-1 or TIMP-2 expression or GC phenotype did not correlate with survival.
  • Prognostic markers are dependent on the lymphoma treatments used.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Matrix Metalloproteinase 9 / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Matrix Metalloproteinase 2 / analysis. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811332.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Neoplasm Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; VB0R961HZT / Prednisone; CHOEP protocol; CHOP protocol
  •  go-up   go-down


70. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M: BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem; 2010 May 27;53(10):4166-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
  • In our continued attempts to identify novel and effective pan-Bcl-2 antagonists, we have recently reported a series of compound 2 (Apogossypol) derivatives, resulting in the chiral compound 4 (8r).
  • Compound 11 (BI-97C1), the most potent diastereoisomer of compound 4, inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.31, 0.32, 0.20, and 0.62 microM, respectively.
  • The compound also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC(50) values of 0.13, 0.56, and 0.049 microM, respectively, and shows little cytotoxicity against bax(-/-)bak(-/-) cells.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14034-9 [16172403.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):970-81 [16909112.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1046-53 [17363497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Bioorg Chem. 2007 Aug;35(4):344-53 [17512966.001]
  • [Cites] Cell Death Differ. 2007 Sep;14(9):1711-3 [17572662.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5828-32 [17353899.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):107-13 [18782651.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):904-13 [19372563.001]
  • [Cites] Cell Death Differ. 2009 Jul;16(7):1030-9 [19390557.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4511-23 [19555126.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11092-9 [10753914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):173-82 [11175750.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nat Rev Drug Discov. 2002 Feb;1(2):111-21 [12120092.001]
  • [Cites] Leukemia. 2003 Jan;17(1):211-9 [12529680.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8758-73 [14647471.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2427-32 [7608907.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Adv Pharmacol. 1997;41:501-32 [9204157.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Prostate. 1998 Mar 1;34(4):275-82 [9496902.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1059-64 [15647352.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):5-6 [16023593.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • (PMID = 20443627.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA149668-01; United States / NCI NIH HHS / CA / CA113318; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / U19 CA113318-04; United States / NCI NIH HHS / CA / R01 CA127641; United States / NCI NIH HHS / CA / CA113318-04; United States / NCI NIH HHS / CA / R01 CA149668-01; United States / NCI NIH HHS / CA / R01 CA097318; United States / NCI NIH HHS / CA / R01 CA149668; United States / NCI NIH HHS / CA / CA149668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypol; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS202533; NLM/ PMC2880850
  •  go-up   go-down


71. Inaba T, Nishimura H, Saito J, Yamane Y, Yuasa S, Hosokawa Y, Fujita N: A case of CD45-negative diffuse large B-cell lymphoma in thyroid gland. Lab Hematol; 2008;14(2):12-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of CD45-negative diffuse large B-cell lymphoma in thyroid gland.
  • CD45, also referred to as the leukocyte common antigen (LCA), is selectively expressed on nucleated hematopoietic cells in healthy individuals.
  • In this paper, we report a rare case of CD45-negative non-Hodgkin's lymphoma (NHL) that affected the thyroid gland.
  • [MeSH-major] Antigens, CD45 / analysis. Lymphoma, Large B-Cell, Diffuse / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18599430.001).
  • [ISSN] 1523-6528
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


72. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis; 2006 Nov 15;194(10):1394-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
  • [MeSH-minor] Antibodies, Viral / blood. Baculoviridae / genetics. Dose-Response Relationship, Immunologic. Double-Blind Method. Female. Hemagglutinins, Viral / genetics. Hemagglutinins, Viral / immunology. Humans. Influenza A Virus, H1N1 Subtype / immunology. Influenza A Virus, H3N2 Subtype / immunology. Influenza B virus / immunology. Lymphoma, B-Cell / immunology. Male. Middle Aged. Neutralization Tests. Vaccines, Synthetic / adverse effects. Vaccines, Synthetic / immunology. Viral Proteins / genetics. Viral Proteins / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054068.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-30039
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Hemagglutinins, Viral; 0 / Influenza Vaccines; 0 / Vaccines, Synthetic; 0 / Viral Proteins; 0 / hemagglutinin fusogenic peptide, influenza virus
  •  go-up   go-down


73. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M: SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene; 2006 Aug 24;25(37):5180-6
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.
  • Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression.
  • Here, we investigated defective negative feedback signaling through the (pre-) B-cell receptor as a possible reason for deregulated V(D)J recombinase activity in B-cell malignancy.
  • On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively.
  • Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V(H)-DJ(H) rearrangements and secondary V(H) replacement.
  • [MeSH-major] Burkitt Lymphoma / genetics. Carrier Proteins / genetics. Lymphoma, B-Cell / genetics. Phosphoproteins / deficiency. Phosphoproteins / genetics. VDJ Recombinases / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Base Sequence. Cell Line, Tumor. DNA Damage. Gene Rearrangement. Genes, Immunoglobulin. Humans. Molecular Sequence Data. Sequence Deletion

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636677.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Carrier Proteins; 0 / Phosphoproteins; EC 2.7.7.- / VDJ Recombinases
  •  go-up   go-down


74. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW: Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res; 2007 Apr 15;13(8):2392-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
  • PURPOSE: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies.
  • A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach.
  • The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells.
  • Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12.
  • For safety purposes, the first three patients did not receive any LAK cell infusions.
  • RESULTS: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone.
  • Two patients achieved a partial remission and five had stable disease.
  • CONCLUSIONS: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.
  • [MeSH-major] Adoptive Transfer. Antibody-Dependent Cell Cytotoxicity / drug effects. Interleukin-2 / therapeutic use. Killer Cells, Lymphokine-Activated / transplantation. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Amino Acid Substitution. Antigens, CD / genetics. Combined Modality Therapy. Humans. Leukapheresis. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / therapy. Receptors, IgG / genetics. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5497 [17875780.001]
  • (PMID = 17438098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / FCGR3A protein, human; 0 / Fc gamma receptor IIA; 0 / Interleukin-2; 0 / Receptors, IgG
  •  go-up   go-down


75. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica; 2007 Oct;92(10):1335-42
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
  • BACKGROUND AND OBJECTIVES: Diffuse large B-cell lymphomas (DLBCL) are common lymphomas that have been classified into three subgroups on the basis of their patterns of gene expression.
  • The aim of this study was to characterize the clinical, biological, immunophenotypic and cytogenetic features of DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement.
  • The clinical features of these cases were examined and morphological, immunohistochemical, flow cytometric and cytogenetic analyses were performed.
  • RESULTS: All patients had aggressive features: B symptoms (81%), ECOG performance status >2 (81%), elevated lactate dehydrogenase (100%), stage IV disease (100%) with at least one extra-nodal localization (bone marrow, blood and central nervous system involvement in 93%, 50% and 50%, respectively) and age-adjusted IPI score of 3 in 81%.
  • Despite intensive chemotherapy regimens (including allogeneic transplants), all patients died of disease progression.
  • Immunophenotyping analysis (CD20, CD10, Bcl-6, Mum-1, Bcl-2 CD138, MIB1, CD19, CD5, CD38 and sIg) was performed and showed DLBCL with a germinal center (GC) profile.
  • The BCL-6 rearrangement was investigated by FISH and found to rearranged in four cases.
  • It is worth searching for the coexistence of dual translocations in Bcl-2-positive DLBCL with unusual aggressive presentation.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Proto-Oncogene Proteins c-myc / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jul;93(7):e53; author reply e54 [18591613.001]
  • [CommentIn] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 18024371.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


76. Harif M, Barsaoui S, Benchekroun S, Bouhas R, Doumbé P, Khattab M, Ladjaj Y, Moreira C, Msefer-Alaoui F, Patte C, Rakotonirina G, Raphael M, Raquin MA, Lemerle J: Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer; 2008 Jun;50(6):1138-42
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP).
  • METHODS: Patients less than 18 years with cytology or histology proven B-cell non-Hodgkin lymphoma were included.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • (PMID = 18213709.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; MACHO protocol
  •  go-up   go-down


77. Couronné L, Schneider P, Picquenot JM, Laberge S, Bastard C, Vannier JP: Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol; 2008 Dec;30(12):959-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation.
  • According to biologic features, there is a substantial "gray zone" between nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs) (Poppema lymphomas) and T-cell/histiocyte-rich B-cell lymphomas (T/HRBCLs).
  • Clinical evolution was complicated by 2 relapses leading to autologous and then to allogeneic bone marrow transplantation.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Histiocytes / pathology. Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Bone Marrow Transplantation. Diagnosis, Differential. Humans. Immunophenotyping. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local / diagnosis. Salvage Therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131792.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
  • Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+).
  • The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients with DLBCL.
  • Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


79. Kusumoto S, Kobayashi Y, Sekiguchi N, Tanimoto K, Onishi Y, Yokota Y, Watanabe T, Maeshima AM, Ishida T, Inagaki H, Matsuno Y, Ueda R, Tobinai K: Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype". Am J Surg Pathol; 2005 Aug;29(8):1067-73
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".
  • Amplification and translocation of the Bcl-2 gene has been detected in a certain subset of diffuse large B-cell lymphomas (DLBCL).
  • The correlations among Bcl-2 protein expression, gene translocation or amplification, and the molecular signature determined by cDNA array are poorly understood.
  • This study examined 25 cases with de novo nodal DLBCL.
  • Interphase fluorescence in situ hybridization (FISH) analysis was performed to evaluate the Bcl-2 gene using IGH/BCL2 and CEP18 centromere probes (Vysis).
  • When extra Bcl-2 gene signals were observed in each tumor cell and when these signals were in proportion to the extra CEP18 probe signals, we regarded the findings as indicating the presence of an additional chromosome 18; when extra Bcl-2 signals were observed but additional CEP18 signals were not, we regarded the findings as indicating the presence of gene amplification.
  • A panel of 3 antigens (CD10, Bcl-6, and MUM-1) was applied to categorize each case as either a "germinal center B-cell (GCB) phenotype" or a "non-GCB phenotype."
  • Of the 25 cases examined, 8 cases (32%) were classified as "GCB phenotype" and 17 cases (68%) were classified as "non-GCB phenotype."
  • A FISH analysis revealed that t(14;18) was detected in 2 of the 8 cases (25%) with the "GCB phenotype" but in none of the 17 "non-GCB phenotype" cases.
  • Extra Bcl-2 gene signals were detected in 7 of the 25 (28%) cases examined: n = 5 for an additional chromosome 18, n = 1 for gene amplification, and n = 1 for additional chromosome 18 + gene amplification.
  • Extra Bcl-2 gene signals were exclusively detected in DLBCL with the "non-GCB phenotype"; these cases, with the exception of one, stained strongly positive for Bcl-2.
  • The DLBCLs with Bcl-2 protein overexpression were classified into at least two heterogeneous molecular groups, based on the results of the FISH analysis.
  • [MeSH-major] Genes, bcl-2 / physiology. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Female. Gene Amplification. Germinal Center / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006802.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem; 2010 Nov 25;53(22):8000-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
  • Overexpression of antiapoptotic Bcl-2 family proteins is commonly related with tumor maintenance, progression, and chemoresistance.
  • Guided by nuclear magnetic resonance (NMR) binding assays, a series of 5,5' substituted compound 6a (Apogossypolone) derivatives was synthesized and identified pan-active antagonists of antiapoptotic Bcl-2 family proteins, with binding potency in the low micromolar to nanomolar range.
  • Compound 6f inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, and Mcl-1 with IC(50) values of 3.10, 3.12, and 2.05 μM, respectively.
  • In a cellular assay, 6f potently inhibits cell growth in several human cancer cell lines in a dose-dependent manner.

  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Eur J Med Chem. 2000 Sep;35(9):805-13 [11006482.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):173-82 [11175750.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nat Rev Drug Discov. 2002 Feb;1(2):111-21 [12120092.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] J Med Chem. 1991 Oct;34(10):2954-61 [1920349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2427-32 [7608907.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29897-902 [8939932.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Adv Pharmacol. 1997;41:501-32 [9204157.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):3-13 [9685174.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):107-13 [18782651.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):92-8 [19236755.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):904-13 [19372563.001]
  • [Cites] Oncol Rep. 2009 Jul;22(1):193-8 [19513523.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4511-23 [19555126.001]
  • [Cites] J Med Chem. 2010 May 27;53(10):4166-76 [20443627.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):171-80 [10096426.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):5-6 [16023593.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • [Cites] Org Lett. 2006 Dec 21;8(26):5919-22 [17165894.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):970-81 [16909112.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1046-53 [17363497.001]
  • [Cites] Bioorg Chem. 2007 Aug;35(4):344-53 [17512966.001]
  • [Cites] J Med Chem. 2007 Jul 12;50(14):3163-6 [17552510.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5828-32 [17353899.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]
  • [Cites] Mol Cancer. 2008;7:20 [18275607.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2192-202 [18645028.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2418-29 [18712728.001]
  • [Cites] Acta Pharmacol Sin. 2008 Dec;29(12):1467-77 [19026166.001]
  • (PMID = 21033669.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA149668-01; United States / NCI NIH HHS / CA / CA113318; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / U19 CA113318-04; United States / NCI NIH HHS / CA / CA113318-04; United States / NCI NIH HHS / CA / R01 CA149668-01; United States / NCI NIH HHS / CA / R01 CA149668; United States / NCI NIH HHS / CA / CA149668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 6,6',7,7'-tetrahydroxy-3,3'-dimethyl-5,5'-bis(4-methylphenethyl)-2,2'-binaphthyl-1,1',4,4'-tetraone; 0 / Antineoplastic Agents; 0 / Bax protein (53-86); 0 / Naphthoquinones; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypolone; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS249613; NLM/ PMC3059195
  •  go-up   go-down


81. Hartmann BL, Winder T, Sandholzer M, Gasser K, Jäger I, Lang AH, Längle M, Hartmann G, Bartenstein C, Luger C: JC papovavirus leukencephalopathy in a patient with B-CLL receiving long-term chemotherapy in combination with an anti-CD20-antibody. J Clin Oncol; 2009 May 20;27(15_suppl):e18007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Our patient was a 64-year-old woman with B-CLL diagnosed in 2000 in state B of Binet treated with 12 cycles of fludarabin until July 2007 in a B-cell and lymphoma-reducing manner.
  • For the reason of progressive disease 3 cycles of rituximab, fludarabin, mitoxantrone, and cyclophosphamide were added (dose reduced causing hematologic toxicity) until October 2007 continuing rituximab once a month up to Mai 2008.
  • RESULTS: In a CT scan mixed response was observed with progressive disease infradiafragmatic and regression supradiafragmatic.
  • Corticosteroids could stop B-symptoms and leads to a distinct shrinkage of the lymphomas within 2 weeks.
  • A lumbar puncture showed no malignant cells and no evidence of inflammation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F: Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood; 2010 Sep 2;116(9):1479-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.
  • We conducted a retrospective collaborative study to cytogenetically characterize splenic marginal zone lymphoma (SMZL) and ascertain the prognostic value of chromosomal aberrations.
  • In conclusion, the cytogenetic profile of SMZL is distinct from other B-cell lymphomas.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, B-Cell, Marginal Zone / genetics. Splenic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Genes, p53. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479288.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


83. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Pedrinis E, Cavalli F, Pinotti G, Zucca E: Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol; 2009 Jun;20(6):1086-93
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.
  • BACKGROUND: Treatment aimed at eradicating Helicobacter pylori infection results in lymphoma remission in most localized gastric mucosa-associated lymphoid tissue (MALT) lymphomas.
  • METHODS: One hundred and five patients with localized gastric MALT lymphoma were initially treated only with H. pylori eradication regimens.
  • Lymphoma responses were graded using the Wotherspoon score.
  • Histological regression of the lymphoma was achieved in 78 of 102 assessable patients [76%, 95% confidence interval (CI): 67% to 84%] with complete remission (score 0-2) in 66 and partial remission (score 3) in 12.
  • At a median follow-up time of 6.3 years, histological remission was consistently confirmed in 33 of 74 assessable patients, while 25 had score fluctuations (from 0 to 4) and 13 presented a lymphoma relapse (score 5).
  • Transformation to a large-cell lymphoma was seen in two cases.
  • Only one patient died of lymphoma after transformation to a high-grade lymphoma.
  • CONCLUSIONS: Helicobacter pylori eradication resulted in complete lymphoma remission in the majority of cases.
  • Long-term clinical disease control was achieved in most patients.
  • A watch and wait policy appears to be safe in patients with minimal residual disease or histological-only local relapse.

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193705.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Weis S, Llenos IC: Primary leptomeningeal B-cell lymphoma of MALT-type in statu nascendi: a case report and review of the literature. Clin Neurol Neurosurg; 2008 Jul;110(7):732-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leptomeningeal B-cell lymphoma of MALT-type in statu nascendi: a case report and review of the literature.
  • A 29-year-old Caucasian female suffering from bipolar disorder, mixed, moderate with psychotic features (DSM-IV 296.64) and panic disorder without agoraphobia (DSM-IV 300.01) died as a result of an accidental overdose.
  • Upon histopathological examination of the brain, as an incidental finding, a small lesion (1mm x 2mm) composed of heterogeneous small lymphocytic cells (CD20-positive) including centrocyte-like cells, a few small lymphocytes and rare immunoblast-like cells was evident.
  • The diagnosis of primary leptomeningeal MALT-type lymphoma was made.
  • This case adds another aspect to the rare entity of primary leptomeningeal lymphomas.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Meningeal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499338.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Number-of-references] 40
  •  go-up   go-down


85. Murga Penas EM, Kawadler H, Siebert R, Frank M, Ye H, Hinz K, Becher C, Hummel M, Barth TF, Bokemeyer C, Stein H, Trümper L, Möller P, Marynen P, Du MQ, Yang X, Hansmann ML, Dierlamm J: A novel fusion of the MALT1 gene and the microtubule-associated protein 4 (MAP4) gene occurs in diffuse large B-cell lymphoma. Genes Chromosomes Cancer; 2006 Sep;45(9):863-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel fusion of the MALT1 gene and the microtubule-associated protein 4 (MAP4) gene occurs in diffuse large B-cell lymphoma.
  • Rearrangements of the MALT1 gene by the t(11;18)(q21;q21) and t(14;18)(q32;q21) are the most frequent structural chromosomal abnormalities in MALT lymphomas.
  • Among 122 diffuse large B-cell lymphomas and 28 Burkitt's lymphomas screened by interphase FISH, we found two cases with a break within MALT1, but without a t(11;18) or a t(14;18).
  • [MeSH-major] Caspases / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16804917.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MAP4; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


86. Buyukberber M, Gulsen MT, Sevinc A, Koruk M, Sari I: Gastrocolic fistula secondary to gastric diffuse large B-cell lymphoma in a patient with pulmonary tuberculosis. J Natl Med Assoc; 2009 Jan;101(1):81-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrocolic fistula secondary to gastric diffuse large B-cell lymphoma in a patient with pulmonary tuberculosis.
  • Gastrocolic fistula secondary to primary gastric lymphoma is a very rare entity.
  • On admission to outpatient clinics, it may be difficult to diagnose gastrocolic fistula, as its clinical symptoms are nonspecific.
  • Histopathological examination of the gastric biopsy was determined to be primary gastric diffuse large B-cell-type non-Hodgkin's lymphoma.
  • In conclusion, persistent vomiting may suggest a probable gastrocolic fistula despite nonspecific clinical findings.
  • In the literature, the present case represents the first report of a gastrocolic fistula due to gastric lymphoma in a patient with tuberculosis at its initial presentation.
  • [MeSH-major] Colonic Diseases / etiology. Gastric Fistula / etiology. Intestinal Fistula / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Stomach Neoplasms / complications. Tuberculosis, Pulmonary / complications


87. Stöcklein H, Smardova J, Macak J, Katzenberger T, Höller S, Wessendorf S, Hutter G, Dreyling M, Haralambieva E, Mäder U, Müller-Hermelink HK, Rosenwald A, Ott G, Kalla J: Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. Oncogene; 2008 Apr 17;27(18):2613-25
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
  • Deletions in the short arm of chromosome 17 (17p) involving the tumor suppressor TP53 occur in up to 20% of diffuse large B-cell lymphomas (DLBCLs).
  • DLBCL patients with complete inactivation of both HIC1 and TP53 may be characterized by an even inferior clinical course than patients with inactivation of TP53 alone, suggesting a functional cooperation between these two proteins.
  • [MeSH-major] Chromosome Deletion. Chromosome Mapping. Chromosomes, Human, Pair 17 / genetics. Kruppel-Like Transcription Factors / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Telomere / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Alleles. Chromosomes, Artificial, Bacterial / genetics. Chromosomes, Artificial, P1 Bacteriophage / genetics. DNA Methylation. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Humans. Quantitative Trait Loci / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982487.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


88. Li L, Li GD, Jiang W, Yang WX, Liu WP, Zhang WY, Li JM, Tang Y: [Expression of BCL-10 protein and the relationship with API2-MALT1 fusion gene in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):678-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of BCL-10 protein and the relationship with API2-MALT1 fusion gene in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue].
  • OBJECTIVE: To investigate the relationship of BCL-10 protein and API2-MALT1 fusion gene in MALT lymphoma.
  • METHODS: Specimens from 86 cases of MALT lymphoma were studied by immunohistochemical staining for BCL-10.
  • RESULTS: In all 10 cases of Hashimoto thyroiditis only cytoplasmic BCL-10 expression in lymphoid cells was observed.
  • In 86 MALT lymphoma cases, 42 cases (48.
  • 8%) exhibited BCL-10 expression in both nucleus and cytoplasm.
  • 7%) of MALT lymphoma.
  • BCL-10 nuclear expression was correlated with API2-MALT1 fusion gene transcript (r = 0.
  • CONCLUSION: BCL-10 nuclear expression is correlated with API2-MALT1 fusion gene expression in MALT lymphoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Follow-Up Studies. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Hashimoto Disease / genetics. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoid Tissue / metabolism. Lymphoid Tissue / pathology. Male. Middle Aged. Respiratory Mucosa / metabolism. Respiratory Mucosa / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274374.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


89. Tanaka Y, Yamabe H, Yamasaki H, Tsuda H, Nagayoshi Y, Kawano H, Kimura Y, Hokamura Y, Ogawa H: A case of reversible ventricular tachycardia and complete atrioventricular block associated with primary cardiac B-cell lymphoma. Pacing Clin Electrophysiol; 2009 Jun;32(6):816-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of reversible ventricular tachycardia and complete atrioventricular block associated with primary cardiac B-cell lymphoma.
  • We report a long-term survival case of primary cardiac lymphoma with reversible ventricular tachycardia (VT) and complete atrioventricular block (C-AVB).
  • He was then diagnosed with primary cardiac lymphoma.
  • [MeSH-major] Atrioventricular Block / etiology. Atrioventricular Block / prevention & control. Heart Neoplasms / complications. Heart Neoplasms / therapy. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / therapy. Tachycardia, Ventricular / etiology. Tachycardia, Ventricular / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545348.001).
  • [ISSN] 1540-8159
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Bosga-Bouwer AG, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P, van den Berg E, Poppema S: Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol; 2006 May;37(5):528-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?
  • We studied a histological homogeneous group of 29 cases with the diagnosis of follicular lymphoma (FL) grade 3B (FL3Bs).
  • In this study, we further characterized the FL3B lymphomas that are currently part of the spectrum of FL in the WHO classification, taking into account other cytogenetical aberrations, immunohistochemistry for P53, bcl2, bcl6, and CD10, rearrangement of the proto-oncogene myc, and mutation of the tumor suppressor gene TP53.
  • The lack of CD10 expression and gain of chromosome 7 in most cases in the other 2 subgroups suggest that those cases have a closer relation to diffuse large B-cell lymphomas.
  • [MeSH-major] Immunophenotyping. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA Mutational Analysis. DNA, Neoplasm / analysis. Genes, myc. Genes, p53. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mutation. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6 / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2007 Jan;38(1):191-2; author reply 192-3 [17169631.001]
  • (PMID = 16647949.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


91. Perez RH, Alonso Farto JC, Arias IA, Regi AR, Perez Vazquez JM: Small rounded B-cell lymphoma of bone presented by limp, with a positive multifocal 99mTc MDP bone scintigraphy pattern and a negative 99mTc HMPAO-labeled leukocytes study. J Pediatr Hematol Oncol; 2008 Jun;30(6):443-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small rounded B-cell lymphoma of bone presented by limp, with a positive multifocal 99mTc MDP bone scintigraphy pattern and a negative 99mTc HMPAO-labeled leukocytes study.
  • In this article, we present a rare case of B-cell bone lymphoma in a child with multifocal asymptomatic lesions detected by bone scintigraphy and a chronic clinical history characterized by limping and fever episodes for over a year.
  • Initially, multifocal osteomyelitis was suspected and antibiotic therapy was administered with no clinical improvement.
  • The biopsy of the main lesion in the left distal femur along with bone marrow cytology established the final diagnosis.
  • This rare case illustrates the utility of routinely low cost-effective nuclear medicine studies like whole body bone scan and 99mTc hexamethylpropyleneamine oxime-labeled leukocytes to orientate similar cases to a correct diagnosis.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Gait. Lymphoma, B-Cell / radionuclide imaging. Technetium Tc 99m Medronate
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Diagnosis, Differential. Humans. Leukocytes / pathology. Male. Osteomyelitis / pathology. Osteomyelitis / radionuclide imaging. Radionuclide Imaging. Technetium Tc 99m Exametazime

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525460.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3B744AG22N / Technetium Tc 99m Exametazime; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


92. Barrans SL, Fenton JA, Ventura R, Smith A, Banham AH, Jack AS: Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement. Haematologica; 2007 Jun;92(6):863-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
  • Strong uniform expression of FOXP1 protein occurs in a subgroup of non-germinal centre (GC) diffuse large B-cell lymphomas (DLBCL).
  • [MeSH-major] Forkhead Transcription Factors / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550867.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


93. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood; 2009 Jan 1;113(1):18-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
  • Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DCs) loaded with killed autologous tumor cells.
  • Six patients had objective clinical responses including 3 continuous complete responses (CRs) and 3 partial responses (PRs), with a median follow up of 50.5 months.
  • Eight patients had stable disease, whereas 4 had progressive disease.
  • Clinical responses were significantly associated with a reduction in CD4(+)CD25(+)FOXP3(+) regulatory T cells, an increase in CD3(-)CD56(dim)CD16(+) natural killer (NK) cells, and maturation of lymphocytes to the effector memory stage in either postvaccination peripheral blood or tumor specimen samples.
  • In partial responding patients, vaccination significantly boosted the IFN-gamma-producing T-cell response to autologous tumor challenge.
  • In one HLA-A*0201(+) patient who achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgH-encoded peptides was also documented.
  • Collectively these results demonstrate that vaccination with tumor-loaded DCs may induce both T- and B-cell responses and produces clinical benefits in indolent NHL patients with measurable disease.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Dendritic Cells / immunology. Immunotherapy, Adoptive. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Immunophenotyping. Killer Cells, Natural / immunology. Male. Middle Aged. Pilot Projects. Quality Control. Recurrence. T-Lymphocytes, Regulatory / immunology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809757.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


94. Siddique K, Bhandari S, Harinath G: Epstein-Barr virus (EBV) positive anal B cell lymphoma: a case report and review of literature. Ann R Coll Surg Engl; 2010 Apr;92(3):W7-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) positive anal B cell lymphoma: a case report and review of literature.
  • [MeSH-major] Anus Neoplasms / virology. Epstein-Barr Virus Infections / complications. Lymphoma, Large B-Cell, Diffuse / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412659.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


95. Wang YT, Su HH, Hou Y, Chu ST, Lai PH, Tseng HH, Lin SJ, Chou YW: Diffuse large B-cell lymphoma of the cerebellopontine angle in a patient with sudden hearing loss and facial palsy. J Chin Med Assoc; 2007 Jul;70(7):294-7
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the cerebellopontine angle in a patient with sudden hearing loss and facial palsy.
  • Primary lymphoma of the cerebellopontine angle (CPA) is rare in the central nervous system.
  • The tumor was removed through left retromastoid craniectomy, and the histopathologic diagnosis of the tumor was confirmed as diffuse large B-cell type malignant lymphoma.
  • After a series of tumor surveys, there was no evidence of other original lymphoma.
  • The patient was treated with chemotherapy (including intra-Ommaya injection with methotrexate and Ara-C and systemic injection with vincristine, methotrexate and ifosfamide) for the primary CPA lymphoma.
  • [MeSH-major] Cerebellar Neoplasms / complications. Cerebellopontine Angle. Facial Paralysis / etiology. Hearing Loss, Sudden / etiology. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631467.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


96. Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL: [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Ai Zheng; 2005 Dec;24(12):1421-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
  • BACKGROUND & OBJECTIVE: CHOP regimen is a standard treatment for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL), and its 5-year overall survival (OS) rate is 30%-40%.
  • Rituximab is a chimeric monoclonal antibody (MoAb) directly against CD20-positive B cells, and has good effect on diffuse large B-cell NHL.
  • Rituximab combined with standard chemotherapy has been approved for treating aggressive B-cell NHL in Europe and the US.
  • This study was to determine efficacy and safety of the combination of Rituximab and CHOP regimen in treating Chinese patients with CD20-positive diffuse large B-cell NHL.
  • Disease progression during treatment was reported for 7 (21.9%) patients in CHOP group and 1 (3.2%) patient in R-CHOP group (P=0.026).
  • CONCLUSION: When compared with standard CHOP alone, the addition of Rituximab to standard CHOP regimen reduces the risk of treatment failure in patients with diffuse large B-cell NHL, and doesn't increase the occurrence of chemotherapy-related adverse events.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351785.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


97. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ: Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol; 2006 Apr;208(5):714-23
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
  • Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable.
  • Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found previously to be strongly associated with clinical outcome.
  • In this study we aimed to develop an algorithm based on expression of GCB/ABC-related proteins CD10, Bcl-6 and MUM1 and apoptosis-inhibiting proteins Bcl-2, XIAP and cFLIP for optimal stratification of DLBCL patients into prognostically favourable and unfavourable groups.
  • Expression of CD10 and cFLIP was associated with better overall survival (both p = 0.03), whereas expression of MUM1, Bcl-2 and XIAP was associated with poor clinical outcome (p = 0.01, p = 0.0007 and p = 0.03, respectively).
  • Multivariate analysis revealed that Bcl-2 was the strongest prognostic marker followed by CD10 and MUM1.
  • Stratification of patients according to a new algorithm based on expression of these three markers improved patient risk stratification into low and particularly high clinical risk groups (p = 0.04 and p < 0.0001, respectively).
  • We conclude that, in our group of primary nodal DLBCLs, a new algorithm, based on expression of the apoptosis-inhibiting protein Bcl-2 and the GCB/ABC-related proteins CD10 and MUM1, strongly predicts outcome in International Prognostic Index (IPI)-low and -high patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Female. Humans. Immunoenzyme Techniques. Interferon Regulatory Factors / metabolism. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400625.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


98. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW: Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem; 2006 Feb 9;49(3):1165-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
  • Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function, is described.
  • The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X(L) and HSA domain III indicated two potential optimization sites for separation of affinities.
  • Modifications at both sites resulted in compounds with improved Bcl-X(L) binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-X(L) with a K(i) of 0.8 nM.
  • In a cellular assay 73R reversed the protection afforded by Bcl-X(L) overexpression against cytokine deprivation in FL5.12 cells with an EC(50) of 0.47 microM.
  • 73R showed little effect on the viability of the human non small cell lung cancer cell line A549.
  • [MeSH-major] Aniline Compounds / chemical synthesis. Antineoplastic Agents / chemical synthesis. Piperidines / chemical synthesis. Sulfonamides / chemical synthesis. bcl-X Protein / antagonists & inhibitors
  • [MeSH-minor] Animals. Biological Availability. Cell Line, Tumor. Drug Screening Assays, Antitumor. Drug Synergism. Fluorescence Polarization. Humans. Magnetic Resonance Spectroscopy. Mice. Mice, SCID. Paclitaxel / pharmacology. Protein Binding. Protein Structure, Tertiary. Serum. Serum Albumin / chemistry. Stereoisomerism. Transplantation, Heterologous. Ultraviolet Rays

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16451081.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(3-dimethylamino-1-phenylsulfanylmethylpropylamino)-N-(4-(4,4-dimethylpiperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide; 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Piperidines; 0 / Serum Albumin; 0 / Sulfonamides; 0 / bcl-X Protein; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


99. Shimizu K, Ishii G, Nagai K, Yokose T, Ishizawa K, Tamaru J, Yoshida J, Nishimura M, Ochiai A: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the thymus: report of four cases. Jpn J Clin Oncol; 2005 Jul;35(7):412-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the thymus: report of four cases.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma in the thymus is extremely rare, and little is known about its clinicopathological features.
  • In this study, we examined four cases of MALT lymphoma in the thymus at our institute in terms of clinicopathological features.
  • Most patients had autoimmune disease or hyperglobulinemia, and they also had cysts in the tumors.
  • We recommend that MALT lymphoma in the thymus should be considered in the differential diagnosis when a cystic thymic mass is found and if the patient is Asian and/or has autoimmune disease or hyperglobulinemia.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / immunology. Autoantibodies / immunology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976071.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Autoantibodies
  •  go-up   go-down


100. Bracht K, Kiefer T, Dölken G, Bednarski PJ: Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status. J Cancer Res Clin Oncol; 2007 Dec;133(12):957-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status.
  • PURPOSE: The aim of this study was to characterize three new, recently established non-Hodgkin lymphoma cell lines (GUMBUS, DOGUM, and DOGKIT), isolated from patients developing high-clinical resistance to cytotoxic therapy, with respect to sensitivity toward 21 antitumor drugs from different classes of action, expression of three ABC transporters: P glycoprotein (Pgp) (MDR1 and ABCB1), multidrug resistance related proteins (MRP1) (ABCC1), and MRP2 (ABCC2), as well as a range of antioxidative enzymes and glutathione (GSH).
  • The results were compared to analogous data from the well-known HL-60 and U-937 cells.
  • METHODS: The MTT assay was used to measure cell growth inhibitory activity.
  • RESULTS: Based on the 50% growth inhibitory values (GI(50) values) of 21 known antitumor agents, the cell lines were sensitive again to chemotherapeutics after being in culture for at least 15-18 weeks.
  • None of the cell lines expressed measurable levels of any of the three transporters investigated and showed only moderate variation in their antioxidative defense system.
  • Furthermore, all three cell lines rapidly acquired resistance to doxorubicin, methotrexate, and cisplatin again in vitro after only 3-5 treatment cycles with the respective drug.
  • CONCLUSIONS: The therapy-resistant lymphoma cell lines GUMBUS, DOGUM, and DOGKIT were sensitive to antitumor agents once again after they had been established in culture.
  • However, their sensitivity to antitumor agents can be rapidly decreased in vitro by either introducing the cells to culture conditions favoring oxidative stress or by exposing the cells at regular intervals to an antitumor drug.
  • The ability of these three cell lines to quickly adapt to toxic insults in their environment is probably the reason why clinical resistance occurred.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Cell Line, Tumor. Drug Resistance, Neoplasm. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Oxidation-Reduction
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacology. Cell Division / drug effects. Female. Humans. Hydrogen Peroxide / pharmacology. Male. Membrane Transport Proteins / metabolism. Middle Aged. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. P-Glycoproteins

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - DoGKiT (CVCL_2023) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - DOGUM (CVCL_2024) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - GUMBUS (CVCL_2051) .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562080.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / multidrug resistance-associated protein 1; 0 / multidrug resistance-associated protein 2; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down






Advertisement